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Summary 
 
The aim of this study was to develop a short form of the 24-item Genetic Counselling 
Outcome Scale (GCOS-24), suitable for use in the clinical setting and in evaluations of 
genetic counselling and testing services. The study comprised four phases. Phase I: 
Cognitive interviews were used to explore interpretability of GCOS-24 items and which 
GCOS-24 items were most valued by the target population. Ten cognitive interviews 
were conducted with individuals affected by or at risk for a genetic condition, recruited 
from patient support groups. Phase II: Quantitative analysis of an existing data set of 
GCOS-24 responses (n = 395), using Classical Test Theory (CTT) methods to identify 
underlying traits, and Item Response Theory (IRT) methods to examine item 
discrimination. Phase III: Item Selection. The results from Phases I & II were used to 
inform the selection of a set of GCOS-24 items. The Rasch rating scale model (Andrich, 
1978) was also used to explore functional problems with the seven-point Likert Scale. A 
six-item questionnaire with a five-point Likert Scale was produced (GCOS-6). In Phase 
IV the reliability and discriminative ability of the new instrument was tested through a 
test-retest study. GCOS-6 displays excellent test-retest reliability (0.788) and moderate 
internal consistency (α = .570). This study represents a potential first step in the 
development of a measure which could be used in the evaluation of technologies and 
services used in genetic counselling and testing services. 
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1.  Introduction 
The goal of this chapter is to present an introduction to the context of this thesis, 
including an outline of why this research was carried out and why it is of significance in 
the field of clinical genetics. The research problem will be described, as well as the 
overall project aim. 
 
 1.1 Context of Research 
Genetic counselling and associated testing services (hereafter shortened to ‘clinical 
genetics services’ (CGS)) is a medical speciality which can offer a number of potential 
benefits to individuals and families affected by possible genetic conditions. Studies 
have provided evidence that patients attend CGS seeking information and a supportive 
relationship, and that the benefits of CGS include relief of uncertainty and feelings of 
vulnerability, increased self-efficacy, and adaptation to the genetic condition in the 
family (Bernhardt et al., 2000; MacLeod et al., 2002; McAllister et al., 2008; Payne et 
al., 2007; Skirton, 2001; Slomp et al., 2017). One stated aim of prenatal genetic 
counselling, for example, is to assist the patient in making decisions regarding invasive 
testing (Beulen et al., 2016).  
Robust and validated measures of these benefits are needed to provide evidence to 
service commissioners about the outcomes of investing in existing CGS or future 
service developments. Evaluations of CGS have traditionally examined outcome 
variables such as information recall, reproductive intentions and decisions made, and 
patient satisfaction (Clarke et al., 1996). Measures of process such as waiting times and 
numbers of patients seen have also been used, as well as the performance 
characteristics of genetics tests (e.g. sensitivity, specificity and predictive values) 
(Clarke et al., 1996; Payne et al., 2008). More recently, clinical genetics professionals 
have contended that the traditional approaches to outcome measurement are not 
relevant or appropriate, and that insufficient attention has been paid to outcomes 
relevant to the population of individuals who use CGS (Clarke, 1996; MacLeod, 2002; 
McAllister et al., 2008; McAllister & Dearing, 2015; Payne et al., 2008). Moreover, 
many of the measures which have been used to evaluate CGS have not undergone 
rigorous psychometric validation, often assessed for internal consistency alone (Payne 
et al., 2008; McAllister & Dearing 2015). 
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 1.2 Patient-Reported Outcome Measures 
Patient-reported outcomes measures (PROMs) are questionnaires designed to 
measure healthcare outcomes directly from the perspective of the patient, and over 
recent years they have been gaining prominence in healthcare valuation across the 
world. In the UK, routine use of PROMs in the NHS was recommended by the 
Department of Health for the purpose of providing data on quality of care (DoH, 2008), 
and this has since been operationalised for all NHS hernia repairs, varicose vein 
treatments, and hip and knee replacements in England (Diness et al., 2017; Judge et al., 
2012; Nuttall et al., 2013). PROMs are also of increasing importance in US healthcare, 
with the Department of Health and Human Services (HHS) and the Food and Drug 
Administration (FDA) now recommending PROMs data should be used to support 
medical product labelling claims (FDA, 2009). The recognised value of PROMs is further 
demonstrated by the Patient Reported Outcomes Measurement Information System 
(PROMIS) initiative, which catalogues validated PROMs for use in evaluating physical, 
mental and social health in adults and children. It is designed to enhance 
communication between clinicians and researchers, and is available in many languages. 
In short, PROMs offer valuable tools for service evaluation and audit of practice. 
Standardised and widely-validated PROMs such as the EQ-5D (Brooks, 1996) or SF-6D 
(Brazier et al., 2002), used for service evaluation across certain branches of healthcare, 
are not appropriate in the context of CGS because they focus on a restricted number of 
outcome domains, including the physical health status of the patient. Certain items 
within the EQ-5D, for example, explore the ability of the respondent to walk about and 
dress themselves; certain items within the SF-6D assess whether health affects physical 
functioning. Many genetic conditions can neither be treated nor cured, and, apart from 
the monitoring or testing for complications of a genetic condition, interventions 
offered by genetic counselling are not expected to affect physical health status. 
Although in some cases patient morbidity or mortality may show improvement in the 
long-term, for example with those who are offered screening or surgery options for 
hereditary cardiac or cancer syndromes, these changes would not be directly 
attributable to genetic counselling and testing. Health-Related Quality of Life (HRQoL) 
is a multi-dimensional concept that includes elements relating to physical, emotional, 
psychological, and social domains of health. HRQoL outcomes are valued by CGS 
patients and clinicians (Payne et al., 2007), and HRQoL instruments have been 
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recommended for use as measures of effect in evaluations of interventions in medical 
genetics (Stevenson & Carey, 2009). 
 
 
 1.3  Research Problem and Project Aim 
The evaluation of CGS requires a robust and valid PROM, capturing relevant outcomes 
which are valued by CGS patients. This study aims to establish a PROM which would be 
appropriate for routine use in audit and clinical evaluations of CGS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 4 of 116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 5 of 116 
 
2.  Literature Review 
 
This chapter presents a description of what genetic counselling and associated testing 
services (CGS) entails, followed by a critical review of the published research regarding 
outcome measures in genetic counselling and testing services. The aim of the review 
was to identify, synthesise and critically appraise the relevant literature, and in doing 
so to justify why this current research project is necessary and of value in the 
advancement of healthcare research. Key terms have been defined, and the aims of 
the project have been refined according to the findings of the review. 
 
2.1  What do we mean by ‘Genetic counselling and associated testing’? 
As far as medical specialities go, genetic counselling boasts a relatively short history. 
Since first being titled as such by Sheldon Reed in 1947 (Reed, 1955), it has gone from 
being an isolated activity to being integrated as a major component of clinical genetics 
and a legitimate branch of healthcare, and the range and complexity of issues which 
the service is now expected to encompass has expanded considerably. In the UK, 
genetic counselling is regarded as an integral part of the genetic testing process, 
strongly recommended by the NHS in most genetic testing situations (Harding, 2016). 
The current gold standard definition for genetic counselling was published in 2006 by 
the Genetic Counseling Task Force of the National Society of Genetic Counselors 
(NSGC) in the US (Resta et al., 2006). The study made use of input from the 
membership, leaders of genetic advocacy groups and genetic professional 
organisations, and was endorsed by the NSGC Board of Directors. The creation was 
spurred by the need to maintain common practice following the advent of genomic 
medicine (Resta et al., 2006), and following the expansion of genetic counselling 
beyond traditional settings (Bennett et al., 2003; Ciarleglio et al., 2003). It reads as 
follows:  
‘Genetic counselling is the process of helping people understand and adapt to the 
medical, psychological and familial implications of genetic contributions to disease. 
This process integrates the following: 
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 Interpretation of family and medical histories to assess the chance of disease 
occurrence or recurrence; 
 Education about inheritance, testing, management, prevention, resources and 
research; 
 Counselling to promote informed choices and adaptation’ (Resta et al., 2006, 
p77). 
Standardised definitions can help to encourage common practice and ensure that 
patients receive appropriate medical care. With that said, genetic counselling is not a 
standardised process, and it should be remembered that definitions may not be 
representative of all situations. As Matloff (1994) demonstrated in a survey of over 200 
genetic counsellors in the US, the content of genetic counselling sessions will vary from 
counsellor to counsellor and from centre to centre. Similarly the focus of the service 
will shift depending on the genetic condition at hand, and specific objectives and 
outcomes will naturally show differences between patients, as shown by Michie et al. 
(1996) who analysed patient expectations, patient concerns, and patient outcomes 
from 131 genetic counselling consultations, and by Macleod et al. (2002) who 
examined counselees’ perceptions of their consultation.  
Furthermore, genetic counselling services vary between countries and cultures 
(Fathzadeh et al., 2008 (Iran); Mohanty & Dias, 2011 (India); Pampols et al., 2016 
(Spain); Temtamy & Hussen, 2017 (Egypt)). Ethical, religious, and moral values can be 
significantly different both intra- and internationally, as can be the standard of 
healthcare available to patients. As such, the process of genetic counselling will be 
shaped by the respective clinical, technological, ethical and societal milieux (Fathzadeh 
et al., 2008 (Iran); Mohanty & Das, 2011 (India); Pampols et al., 2016 (Spain); Temtamy 
& Hussen, 2017 (Egypt)). Although the NSGC definition may represent the speciality 
from the perspective of those individuals in the US at that time, certain components 
may be lacking or of limited relevance in, say, Egypt or India. For instance, the NSGC 
definition does not mention spiritual beliefs. Whilst this may be of lesser, and arguably 
diminishing importance in Western societies such as the UK, US, Canada and Australia, 
in other cultures this could be a significant consideration to address in counselling 
sessions and as such would be a priority for inclusion in a definition. 
In the UK, one of the key features of modern genetic counselling is that the service is 
centred around the patient and their family members (Hough, 2002; Middleton et al., 
Page 7 of 116 
 
2015; Ormond, 2013; Tluczek et al., 2011). A predominantly ‘non-directive’ approach is 
taken, meaning that the counsellor does not try to guide the patient towards any 
particular decision, for example whether to terminate a pregnancy or to have a 
genomic test. Instead, the counsellor works with the patient to educate and inform, in 
order to build an understanding of what it means to have a genetic condition in the 
family and what options are available to them. 
“It involves a person-centred approach where the genetic counsellor helps the 
patient to incorporate the genetic information into their lives, adjust to it, 
rationalise it, think through how they want to act on it and rehearse how they 
wish to explain it to relatives.” (Hough, 2002. p51) 
Genetic counselling patients may likely have a number of questions and concerns, and 
may carry considerable emotional distress (Clarke et al., 1996; Duric et al., 2003; 
Hamilton et al., 2009; Nordin et al., 2011). As described by McCarthy-Veach et al. 
(2003) in their genetic counselling practice manual, a patient may come for genetic 
counselling at one of the most vulnerable moments in their life. Their child may have 
been diagnosed with a neurodegenerative condition; there may be fear over the 
potential effects of a hereditary trait; or there may be grief if a genetic condition has 
resulted in the premature death of a family member. It is therefore essential for 
genetic counsellors to listen and communicate effectively with their patients, to exhibit 
sensitivity and compassion, and to provide emotional support where necessary. 
Genetic testing is a type of medical test which involves the study of a person’s DNA. It 
usually involves having a sample of blood or tissue taken, and may be carried out to 
diagnose a genetic condition, to help determine the chances of developing a genetic 
condition, or to determine whether a person is a carrier of a genetic mutation. In some 
cases genetic testing can be performed to find out the likelihood of a baby being born 
with a certain genetic condition. Examples of prenatal testing processes include 
amniocentesis, whereby cells are extracted from the mother’s womb using a needle, 
chorionic villus sampling, which involves the removal and testing of placental cells, and 
cell-free fetal DNA screening (also called non-invasive prenatal screening), which 
detects defects in the fetal DNA that is released by the placenta into the mother’s 
bloodstream during pregnancy. A referral to genetic testing will usually be 
accompanied by a referral to genetic counselling, allowing individuals to discuss the 
risks, benefits and limitations of genetic testing with a trained professional. 
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Although commonly used interchangeably, the terms ‘genetics’ and ‘genomics’ are not 
synonymous. ‘Genetics’ is the study of heredity, of the genes people inherit and pass 
down through their family. ‘Genomics’ refers to the study of all genes within an 
organism, including their functions and relationships. There is currently debate over 
whether ‘genomic counselling’ and ‘genomic testing’ are becoming ever-more 
appropriate terms as we transition from single-gene focused genetic counselling and 
testing to the routine incorporation of genomic medicine (Ormond, 2013). For the 
purposes of this thesis, the traditional terminology of ‘genetic counselling’ and ‘genetic 
testing’ has been used throughout. 
In summary, genetic counselling is the process of helping people understand and adapt 
to the medical, psychological and familial implications of genetic contributions to 
disease. Specific objectives and outcomes may vary from patient to patient, and may 
be influenced by a number of factors such as the condition at hand and geographical 
location, but current practice recommends a non-directive, patient-centred approach 
should be taken in order to help build an understanding of what it means to have a 
genetic condition in the family and what options are available to them. Genetic testing 
can be used to confirm or rule out a suspected genetic condition or help to determine a 
person’s chance of developing or passing on a genetic disorder. 
 
 2.2  Literature Search Methodology 
 2.2.1 Introduction 
The overall aim of this study, as stated on page three, was to establish a PROM which 
would be appropriate for routine use in audit and clinical evaluations of CGS. However, 
before jumping into the often arduous and time-consuming task of creating a novel 
health measurement scale, it is recommended that researchers should first look for 
existing validated measures (DeVellis, 2011; Streiner & Norman, 2008). 
Prior to this project, the only published systematic review of outcome measures in CGS 
had been carried out by Payne et al. (2008), a study which identified 67 validated 
outcome measures and concluded that no single measure at the time encompassed all 
aspects of the potential benefits from using a CGS. A more recent review by McAllister 
& Dearing (2015) identified additional measures, but results were used specifically to 
analyse outcome domains. Over the last ten years, the speciality of clinical genetics has 
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seen rapid advances. Existing technologies have improved and novel technologies have 
appeared, and our collective knowledge about how genetics might influence disease 
has increased. Within clinical practice, genetic testing is increasingly being performed 
outside the traditional bounds of CGS and is now moving into other specialities. This 
process is referred to as ‘mainstreaming genetics’ and is occurring in the context of 
cancer predisposition genes (Rahman, 2014), paediatrics (Valente et al., 2008), and 
neurogenetic testing (Lo et al., 2014). Furthermore, recent economic evaluations in 
CGS have found the high degree of heterogeneity in outcome measures as being a 
principal methodological limitation (Djalalov et al., 2011; D’Andrea et al., 2015). The 
aim of the following literature review was therefore to provide a full, thorough, and 
current account of validated outcome measures which have been used in CGS. In other 
words, the question driving the review was: 
‘Is there an existing patient-reported outcome measure which would be 
appropriate for routine use in audit and clinical evaluations of CGS?’ 
 
 2.2.2 Search Design 
The aim of this search was to identify validated outcome measures which had 
previously been used in the evaluation of CGS. An outcome measure was defined as: 
‘any instrument used to measure, evaluate or assess the impact of CGS on the patient’. 
The reason for only including validated outcome measures was that validation is a 
requirement of robust evaluations. For the purposes of this review, validation was met 
if a measure had passed some form of psychometric assessment. 
Being an unfunded MPhil project, this review was not intended to be a systematic 
review; no formal meta-analysis of included articles was conducted and multiple 
independent reviewers were not used. The scope of the review was limited to 
published works in English which were available online, either freely or through Cardiff 
University access. Given time constraints, the period of search and writing was limited 
to Jun 2017 – Jun 2018. 
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 2.2.3 Search Strategy 
An electronic search of The Cardiff University Ovid database from 1940 to present was 
used as the primary resource, but further databases such as Embase (1980 to present), 
the NHS Health Economic Evaluations Database (1900 to present), Medline (1966 to 
present) and the Cochrane database (1900 to present) were also utilised following 
reference to the systematic review of Payne et al. (2008). Search terms included: 
“genetic”; “genomic”; “counsel(l)ing”; “testing”; “clinical genetics”; “outcomes”; 
“patient outcomes”; “patient reported outcomes”; “PROM”; “measure”; “survey”; 
“questionnaire”; “scale”; and terms were again cross-referenced with Payne to check 
for omissions. Overall, the search strategy was put together through consultation with 
supervisors MM & KP, and using the existing systematic review of Payne et al. (2008). 
 2.2.4 Selection and Extraction 
An initial screen of titles and abstracts was carried out by one reviewer (PG), and 
articles were rejected if they were clearly not relevant to outcome measures in CGS. If 
relevance was uncertain, the full text was located and examined. Articles met the 
inclusion criteria if a validated outcome measure was created or applied for the 
purpose of evaluating some aspect of CGS. Articles were excluded if they were not 
written in English, if the outcome measure was not validated, or if the measure was not 
appropriate for use within routine CGS. For the purpose of this study, the completion 
of any psychometric test was sufficient to meet the validity criteria. 
If a validated outcome measure was identified, a tailored spreadsheet was then used 
to extract information about the measure. The degree of psychometric validation was 
noted, as was the purpose of the measure. 
 
2.3  Results 
The search methodology identified 151 titles and abstracts which appeared to be 
relevant and which were chosen for more detailed examination. From these, 86 papers 
were selected for inclusion in the final review. A total of 82 validated outcome 
measures were referred to in these 86 studies (Table 2.1). 
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Table 2.1: Validated outcome measures used in the evaluation of clinical genetics services 
Outcome measure Primary Source(s) Purpose Type of measure 
Anticipated impact of results 
 
Hailey et al. (2000) 
Lerman et al. (1995) 
To assess the likelihood of a variety of possible psychological 
reactions to a positive and negative test result.  
Rating scale 
Genetics specific 
Appropriateness of genetic 
testing delivery 
Andrea et al. (2018) To investigate the appropriateness of genetic testing delivery and 
post-testing healthcare pathways. 
Rating scale 
Genetics specific 
Assessment of benefits and risk 
of breast cancer testing 
Hailey et al. (2000) 
Lerman et al. (1995) 
To assess the perceived benefits and risks of genetic testing.  Rating scale 
Genetics specific 
Audit Tool for Genetic Services  Skirton et al. (2005) To measure outcomes of clinical genetics services.  Rating scale 
Genetics specific 
Beck Depression Inventory (BDI)  
 
Su et al. (2009) To measure the intensity of depression in psychiatrically diagnosed 
patients and for detecting depression in normal populations.  
Rating scale 
Non-genetics specific 
Beliefs About Breast Cancer 
Genetic Testing  
Bowen et al. (2002) To measure specific beliefs about breast cancer genetic testing.  Rating scale 
Genetics specific 
Body Image/Sexuality Scale 
(BISS) 
Lodder et al. (2002) 
Van Oostrum et al. (2003)  
 
To assess body image and general sexual functioning Rating scale 
Non-Genetics specific 
(Breast) Cancer Attitude 
Inventory (CAI) and Anxiety sub-
scale (BCANX)  
Berrenberg (1991) 
Hailey et al. (2000) 
To assess attitudes towards cancer. Rating scale 
Non-genetics (cancer) specific 
Breast cancer (hereditary) 
concern  
Stalmeier et al. (1999) To determine concern about breast cancer Rating scale 
Genetics specific 
Breast Cancer Genetic 
Counselling Knowledge 
Erblich et al. (2005) To assess knowledge of information generally provided during 
breast cancer genetic counselling. 
True/False & Multiple Choice 
Genetics specific 
12 
 
Outcome measure Primary Source(s) Purpose Type of measure 
Questionnaire (BGKQ)  
Breast Cancer Worry  / Cancer 
Worry Scale 
Lerman et al. (1991) 
Van Oostrum et al. (2003) 
To assess dimensions of cancer worry Rating scale 
Non-genetics (cancer) specific 
Brief Symptom Inventory  Derogatis & Melisaratos (1983) To assess psychological symptom patterns in normal populations 
and in psychiatric patients.  
Rating scale 
Non-genetics specific 
Cancer Anxiety and 
Helplessness Scale 
 
Kash et al. (1992) To assess women’s general cancer anxiety and sense of 
helplessness.  
Rating scale 
Non-genetics specific 
Center for Epidemiologic 
Studies Depression-Scale (CES-
D) and brief form  
Radloff (1977) 
Ross & Mirowsky (1984) 
To measure depressive symptomatology in the general population 
rather than the assessment for diagnosis at clinical intake and/or 
evaluation of severity of illness over the course of treatment. 
Rating scale 
Non-genetics specific 
Clinical Genetics Satisfaction 
(CGS) indicator. 
Zellerino et al. (2009) To evaluate patient satisfaction with genetic counselling. Rating scale 
Genetics specific 
Decision Evaluation Scale Stalmeier et al. (2005) To assess how patients evaluate their medical treatment choice.  Rating scale 
Non-genetics specific 
Decisional Conflict Scale (DCS)  O’Connor (1995) To measure decisional conflict, which is a state of uncertainty about 
the course of action to take.  
Rating scale 
Non-genetics specific 
Decision making process  Brain et al. (2005) 
Michie et al. (1997) 
To measure the extent to which women thought or ‘agonised’ about 
the decision.  
Rating and multiple-choice 
Genetics specific 
Desire to participate in the 
shared decision making program  
Stalmeier et al. (1999) To measure desire to participate in the shared decision making 
program 
Rating scale 
Genetics specific 
Emotional reaction to the 
program information  
Stalmeier et al. (1999) To measure the emotional reaction to information given on the 
shared decision making program 
Rating scale 
Genetics specific 
13 
 
Outcome measure Primary Source(s) Purpose Type of measure 
Evaluation of practical issues 
and responsibilities. 
Otten et al. (2016) To assess experiences with preparing for online counselling (e.g. 
clarity of the instructions email). 
Multiple-choice 
Genetics specific 
Expectations of online 
counselling 
Otten et al. (2016) To assess patients’ expectations of online counselling. Rating scale 
Genetics specific 
Family Environment Scale (FES)  Moos & Moos (1994) 
Halvorsen (1991) 
Designed to measure the social-environmental characteristics of all 
types of families.  
Rating scale 
Non-genetics specific 
Functional Assessment of 
Cancer Therapy-General 
(FACT)  
Cella et al. (1993) 
Brady et al. (1997) 
To measure quality of life in patients with cancer. There is also a 
scale specific to breast cancer.  
Rating scale 
Non-genetics specific 
General Health Questionnaire 
(GHQ)  
Goldberg & Williams (1988) 
Goldberg & Hillier (1979) 
To detect those with a diagnosable psychiatric disorder. It looks at 
two areas: inability to carry out one’s normal ‘healthy’ functions and 
the appearance of new phenomena of a distressing nature.  
Rating scale 
Non-genetics specific 
Genetics Appointment Patient 
Satisfaction Score (GAPPS) 
Westwood et al. (2012) To test whether primary care genetic-led genetics education 
improves both non-cancer and cancer-referral rates. 
Rating scale 
Genetics specific 
Genetic Counselling Outcome 
Scale (GCOS-24) 
McAllister et al. (2011b) To capture empowerment, a construct encompassing many patient 
outcomes from CGS. 
Rating scale 
Genetics specific 
Genetic Counseling Satisfaction 
Scale (GCSS)  
Tercyak et al. (2001) To assess patient satisfaction with the process and content of 
genetic counselling 
Rating scale 
Genetics specific 
Genetic Knowledge Index (GKI)  Furr & Kelly (1999) To measure level of genetic knowledge, not specific to a genetic 
disease. 
Rating scale 
Genetics specific 
Global Severity Index (GSI) of 
the Symptom Check List-90 
(SCL90)  
Derogatis (1983) The SCL-90R was designed to reflect the psychological symptom 
patterns of psychiatric and medical patients. To measure the degree 
to which they suffered from psychological complaints 
Rating scale 
Non-genetics specific 
Health Beliefs Model (screening Kash et al. (1992) To assess perceived susceptibility to disease, severity of disease, Rating scale 
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Outcome measure Primary Source(s) Purpose Type of measure 
and breast cancer) 
 
benefits of intervention, risks of intervention, and practical obstacles 
to intervention.  
Non-genetics specific 
Health Orientation Scale  
 
Woolridge & Murray (1989) Designed to objectively appraise the psychological implications of 
identification as a sickle cell gene carrier. Also used to assess the 
emotional implications of being a carrier of the CF-gene 
Rating scale 
Genetics specific 
Hopkins Symptom Checklist 
(HSCL)  
Derogatis et al. (1974) To assess the presence and severity of anxiety and depression 
symptoms over the previous month. It is a self-report symptom 
inventory.  
Rating scale 
Non-genetics specific 
Hospital Anxiety and Depression 
Scale (HADS)  
Zigmond & Snaith (1983) 
Van Oostrum et al. (2003) 
Self-assessment mood scale designed for use in non-psychiatric 
hospital patients to detect states of depression and anxiety.  
Rating scale 
Non-genetics specific 
Illness Perception Questionnaire 
(IPQ) 
Cho et al. (2012) To measure perceived control over risk. Rating Scale 
Non-genetics specific 
Impact of Event Scale (IES)  Horowitz et al. (1979) 
Van Oostrum et al. (2003) 
To evaluate current subjective distress for any life event. The 
wording is not anchored to a specific occurrence but to the particular 
qualities of conscious experience that encompass all such events.  
Rating scale 
Non-genetics specific 
Intention to act upon shared 
decision making program  
Stalmeier et al. (1999) To measure the intention to act upon the shared decision making 
program 
Rating scale 
Genetics specific 
Knowledge About Breast Cancer  Donovan & Tucker (2000) 
Stager (1993) 
Vaeth (1993) 
To assess women’s knowledge of several dimensions of breast 
cancer.  
Rating scale 
Generic 
Knowledge about genetic testing 
for inherited cancer  
Benkendorf et al. (1997) 
Lerman et al. (1996) 
To assess knowledge of inheritance of breast-ovarian cancer 
susceptibility and genetic testing.  
True/false rating 
Genetics specific 
Knowledge about genetic risk for 
breast cancer  
Donovan & Tucker (2000) To assess women’s knowledge about the hereditary nature of 
breast cancer and the increased risk of breast and ovarian cancer 
Rating scale 
Genetics specific 
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Outcome measure Primary Source(s) Purpose Type of measure 
 associated with altered BRCA1 or BRCA2 gene.   
Knowledge Scale about Breast 
(and Ovarian) Cancer and 
Hereditary 
Ondrusek et al. (1999) To test general knowledge about breast cancer and hereditary 
breast cancer among women at low to moderate risk of hereditary 
breast cancer.  
Rating scale 
Non-genetics specific 
Life Orientation Test (LOT)  
 
Scheier et al. (1994) 
Carver et al. (1994) 
To measure the level of optimism in one’s outlook on life Rating scale 
Non-genetics specific 
Measure of Counselees’ 
Knowledge of Down Syndrome  
Braitman & Antley. (1978) To measure counselees’ knowledge and/or understanding of Down 
syndrome 
Multiple choice 
Genetics specific 
Medical Communication 
Behaviour System (MCBS) 
Wolraich et al. (1986) To assess physician-patient interactions that involve giving 
distressful information. 
Rating scale 
Genetics specific 
Medical Interview Satisfaction 
Scale - modified (MISS) 
Wolf et al. (1978) To assess the patient’s perception of a particular care encounter 
rather than satisfaction with medical care in general 
Rating scale 
Non-genetics specific 
Medical Outcomes Short-Form 
Survey (SF-36 and SF-12) 
Ware (1993) 
Jenkinson et al. (1996) 
To measure quality of life.  Rating scale 
Non-genetics specific 
Medical Outcomes Study (MOS) 
Social Support Survey  
Sherbourne & Stewart (1991) To measure the current availability of social support Rating scale 
Non-genetics specific 
Monitoring Blunting Style Scale 
(MBSS) 
Miller (1987) To determine information-seeking coping style.  True/false rating 
Non-genetics specific 
Minnesota Multiphasic 
Personality Inventory (MMPI) 
Graham (1987) To assess general personality profile. True/false 
Non-genetics specific 
Modified Maternal Serum 
Screening Knowledge 
Questionnaire (MSSKQ)  
Goel et al. (1996) To assess knowledge about maternal serum screening. Modified to 
assess knowledge of prenatal testing in general rather than 
maternal serum screening 
Rating scale 
Genetics specific 
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Outcome measure Primary Source(s) Purpose Type of measure 
modified Tolerance for 
Ambiguity Scale (TFA)  
Geller et al. (1993) To measure ambiguity tolerance as a more general personality trait. 
Intolerance for ambiguity has been defined as ‘the tendency to 
perceive situations that are novel, complex or insoluble, as sources 
of threat.’ 
Rating scale 
Non-genetics specific 
Multidimensional Impact of 
Cancer Risk Assessment 
(MICRA)  
Cella et al. (2002) To assess concerns and psychosocial issues associated with 
genetic testing for cancer risk 
Rating scale 
Genetics specific 
Openness to Discuss Cancer in 
the Family Scale (ODCFS)  
Mesters et al. (1997) 
Van Oostrum et al. (2003) 
To assess openness of communication about cancer (and cancer 
genetic test result) in the nuclear family (partner and children) and 
the family of origin (parents, siblings). 
Rating scale 
Non-genetics specific 
Patient health questionnaire 
(PHQ-9) 
Meiser et al. (2013) To evaluate individuals with a family history of depression. Rating Scale 
Non-genetics specific 
Patient Satisfaction with Genetic 
Counselling 
Brain et al. (2000) 
Shiloh et al. (1990) 
To assess patient satisfaction with the genetic counseling process.  Rating scale 
Genetics specific 
Penn State Cancer Genetics 
Program Survey 
Kausmeyer et al. (2006) To assess sources of patient referrals, patient satisfaction and 
expectations, changes in risk perception and decision making based 
on knowledge gained from the cancer risk-assessment. 
Multiple choice 
Genetics specific 
Perceived-Devaluation-
Discrimination-Scale (PDDS) 
Meiser et al. (2013) To assess perceived stigma of depression. Rating Scale 
Non-genetics specific 
Perceived personal control 
(PPC)  
Berkenstadt et al. (1999) 
Otten et al. (2016) 
To measure PPC. Rating scale 
Genetics specific 
Perceived Risk of Breast Cancer Brain et al. (1999) To assess perceived personal risk of developing breast cancer.  Rating scale 
Generic 
Perceptions of the benefits, 
limitations and risks of genetic 
Donovan & Tucker (2000) 
Hughes et al. (1997) 
To assess perceptions of the benefits, limitations and risks of 
genetic testing for breast-ovarian cancer risk. 
Rating scale 
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Outcome measure Primary Source(s) Purpose Type of measure 
testing Audrain et al. (1995) Genetics specific 
Pharmacogenetics in Psychiatry 
follow-up questionnaire (PIP-
FQ) 
Walden et al. (2015) To examine treatment outcomes in psychiatric care after genetic 
information was provided to patients. 
Rating scale 
Genetics specific 
Profile of Mood State (POMS)  
 
McNair et al. (1981) To measure mood states in psychiatric outpatients and for 
assessing changes in such patients. It is also used in non-patient 
populations.  
Rating scale 
Non-genetics specific 
Prostate cancer genetic 
screening survey  
Doukas (2004) To explore what values and expectations influence the intention of 
men to undergo genetic testing for prostate cancer risk 
Rating scale 
Genetics specific 
Psychological Adaptation to 
Genetic Information Scale 
(PAGIS)  
Read et al. (2005) To measure multiple dimensions of psychological adaptation to 
genetic information to facilitate evaluation of the efficacy of 
counseling and supportive interventions and to identify people at 
risk for coping difficulties.  
Rating scale 
Genetics specific 
Psychological Consequences 
Questionnaire (PCQ) 
Cockburn et al. (1992) To assess the psychological consequences of breast 
mammography on well-being 
Rating scale 
Non-genetics specific 
Quality of Care Through the 
Patients’ Eyes (QUOTE)-gene
CA 
Pieterse et al. (2005) To measure the needs and preferences in genetic counseling for 
hereditary cancer before their first consultation.  
Rating scale 
Genetics specific 
Risk comprehension and 
subjective knowledge of women 
in the shared decision making 
program  
Stalmeier et al. (1999) To assess risk comprehension and subjective knowledge of the 
women in the shared decision making program 
Rating scale 
Genetics specific 
Rosenberg Self-Esteem Scale  Rosenberg (1965) 
Curbow & Somerfield (1991) 
Global measure of self-esteem considered to be an indicator of 
psychological adjustment. This measure was originally developed to 
measure adolescents' global feelings of self-worth or self-
acceptance.  
Rating scale 
Non-genetics specific 
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Outcome measure Primary Source(s) Purpose Type of measure 
Satisfaction with Decision Scale  
 
Brain et al. (2005) 
Holmes-Rovner et al. (1996) 
To measure satisfaction with a medical decision.  
Developed in the context of postmenopausal hormone-replacement 
therapy decisions. 
Rating scale 
Non-genetics specific 
Satisfaction with Genetic 
Counselling Questionnaire 
Hilgart et al. (2012) To evaluate the impact of cancer genetic risk-assessment services 
on patients at risk of familial breast cancer. 
Rating scale 
Genetics specific 
Satisfaction with shared decision 
making program  
Stalmeier et al. (1999) To measure the level of satisfaction with the shared decision making 
program 
Rating scale 
Genetics specific 
Self-rating Depression Scale 
(SDS)  
Zung (1965) To measure, using self-rating and interviewer rating, depressive 
disorder. 
Rating scale 
Non-genetics specific 
Shared decision making 
program rationale acceptability  
Stalmeier et al. (1999) To measure the acceptability of the rationale for the shared decision 
making program 
Rating scale 
Genetics specific 
Short-form Health Survey (SF-
12) 
Hubalek et al. (2016) To examine long-term psychosocial consequences and counsellees’ 
satisfaction after genetic counselling for breast and ovarian cancer. 
Rating Scale 
Non-genetics specific 
Short-form Health Survey (SF-
36) 
Bowen & Powers (2010) To measure perceived quality of life. Rating Scale 
Non-genetics specific 
Spielberger State Trait Anxiety 
Inventory (STAI) and state scale 
(STAI-State)  
 
Spielberger et al. (1970) 
Marteau & Bekker (1992) 
To measure anxiety. The STAI differentiates between the temporary 
condition (state anxiety) and the more general and long-standing 
condition (trait anxiety). Adapted for use in children.  
Rating scale 
Non-genetics specific 
Spiritual Well-Being Scale 
(SWBS)  
Ellison & Smith (1991) 
Gioiella et al. (1998) 
To assess personal spiritual meaning and satisfaction. Rating scale 
Non-genetics specific 
Subjective Quality of Life Profile 
(SQLP)  
Dazord (1995) To assess subjective quality of life in patients or healthy people and 
explore the various dimensions of quality of life. 
Rating scale 
Non-genetics specific 
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Outcome measure Primary Source(s) Purpose Type of measure 
Telemedicine Satisfaction 
Questionnaire (TSQ) 
Otten et al. (2015) To measure expected satisfaction with Telemedicine and perceived 
user satisfaction. 
Rating scale 
Genetics specific 
Tennessee Self-Concept Scale  Fitts (1965) The scale is intended to summarize an individual's feeling of self-
worth, the degree to which the self-image is realistic, and whether or 
not that self-image is a deviant one.  
Rating scale 
Non-genetics specific 
Utrechtse Coping List (UCL)  
 
 
 
Westbrook (1979) To evaluate coping strategies such as: active coping, palliative 
coping, avoiding reactions, social support seeking, depressive-
regressive coping, expression of emotions or anger and comforting 
ideas. 
Rating scale 
Non-genetics specific 
Worry Interference Scale (WIS) Trask (2001) To assess the degree to which thoughts about breast cancer are 
perceived as interfering with the respondents’ daily functioning.  
Rating scale 
Genetics specific 
 
Adapted from Payne et al. (2008) Outcome Measurement in Clinical Genetics Services: A systematic review of validated measures. 
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  2.3.1 Outcome Measures: General Properties 
Table 2.1 presents all 82 validated outcome measures identified in this literature 
review. Half (n=41; 50.0%) of the measures can be described as being ‘genetics-
specific’, i.e. they contain items which specifically refer to genetics or a genetic 
condition. Similarly, over half (n=46; 56.1%) were used in studies that evaluated CGS 
with respect to inherited cancers, primarily breast cancer. The style of questionnaire 
varies, but in general they are composed of a series of statements that require a rating 
on a scale. For example, in Benkendorf’s measure ‘Knowledge about genetic testing for 
inherited cancer’ (Benkendorf et al., 1997) one statement says: “A person should be 
able to get a genetic test even if their doctor recommends against it.” Respondents are 
then asked to (i) Strongly Agree; (ii) Agree; (iii) Disagree; or (iv) Strongly Disagree. 
These types of rating scales are known as ‘Likert Scales’. Four instruments provided 
respondents with multiple choice options, for example the measure of Decision-making 
process developed by Michie et al. (1997). This scale contained three multiple-choice 
questions, designed to assess the time spent thinking about whether or not to have a 
test, the number of people this was discussed with, and how many reasons (for or 
against) were considered by the respondent. Three measures offered True/False 
options. 
  2.3.2 Outcome Measures: Outcome Domains 
A variety of different outcome domains are captured by these instruments, for 
example satisfaction with genetic counselling (Shiloh et al., 1990), knowledge about 
genetic testing for inherited cancer (Lerman et al., 1996), and psychological adaptation 
to genetic information (Read et al., 2005). Psychological or emotional domains were 
particularly common, with over 20 measures being specifically designed to capture 
concepts such as depression, anxiety or worry. Similarly, 11 measures examine patient 
knowledge with regard to the condition, risk figures, or testing interventions, and 12 
measures examine patient satisfaction. Two instruments study outcomes from the 
perspective of the physician: the modified Tolerance for Ambiguity Scale (Geller et al., 
1993) and the Pharmacogenetics in Psychiatry Follow-up Questionnaire (PIP-FQ) 
(Walden et al., 2015). Of the 82 instruments identified, only three encompass a wide 
range of potential patient benefits from CGS: The Audit Tool for Genetics Services 
(Skirton et al., 2005), the Perceived Personal Control (PPC) questionnaire (Berkenstadt 
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et al., 1999), and the Genetic Counselling Outcome Scale (GCOS-24) (McAllister et al., 
2011b). 
  2.3.3 Outcome Measures: Validation 
Table 2.2 summarises the extent of psychometric validation for the 82 outcome 
measures identified in this review. Approximately one quarter (n=21; 25.6%) were 
assessed for internal consistency alone. Internal consistency is a reliability statistic, 
denoting the degree of correlation between items in a scale. It has become the primary 
method of estimating the reliability of multi-item scales, and is indexed using 
Cronbach’s coefficient alpha (Frost et al., 2007). The internal consistency value is 
commonly interpreted as indicating whether items which propose to measure a certain 
dimension do in fact measure the same dimension as each other. The remaining 
measures underwent more extensive psychometric assessment, for example content 
validity (n=25) and construct validity (n=29), but there was limited assessment of 
sensitivity to change (n=6) or interpretability (n=2) – key requirements for any 
questionnaire intended for use as a PROM (Mokkink et al., 2010; Terwee et al., 2012). 
Definitions for these terms are provided in Table 2.3. 
Table 2.2: Validation of Outcome Measures Identified in the Literature Review 
Outcome measure Primary Source(s) Validation 
Anticipated impact of results Hailey et al. (2000) 
Lerman et al. (1995) 
Internal Consistency 
Appropriateness of Genetic Testing 
Delivery 
Andrea et al. (2018) Face Validity (part) 
Assessment of benefits and risk of breast 
cancer testing  
Hailey et al. (2000) 
Lerman et al. (1995) 
Internal Consistency 
Audit Tool for Genetic Services  Skirton et al. (2005) Face Validity 
Content Validity 
Beck Depression Inventory (BDI)  
 
Su et al. (2009) Internal Consistency 
Content Validity 
Construct Validity 
Criterion Validity 
Beliefs About Breast Cancer Genetic 
Testing  
Bowen et al. (2002) Internal Consistency 
Body Image/Sexuality Scale (BISS)  Van Oostrum et al. (2003)  
Lodder et al. (2002) 
Internal Consistency 
Retest Reliability  
(Breast) Cancer Attitude Inventory (CAI) Berrenberg (1991) Internal Consistency 
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and Anxiety sub-scale (BCANX)  Hailey et al. (2000) Retest Reliability 
Construct Validity 
Breast cancer (hereditary) concern  Stalmeier et al. (1999) Internal Consistency 
Breast Cancer Genetic Counselling 
Knowledge Questionnaire (BCGKQ-27)  
Erblich et al. (2005) Internal Consistency 
Content Validity 
Criterion Validity 
Breast Cancer Worry  Lerman et al. (1991); Van 
Oostrum et al. (2003) 
Internal Consistency  
Retest Reliability 
Brief Symptom Inventory  Derogatis & Melisaratos (1983) Internal Consistency 
Retest Reliability 
Cancer Anxiety and Helplessness Scale Kash et al. (1992) Internal Consistency 
Center for Epidemiologic Studies 
Depression-Scale (CES-D) 
Radloff (1977) 
Ross & Mirowsky (1984) 
Internal Consistency 
Retest Reliability 
Construct Validity 
Clinical Genetics Satisfaction (CGS) 
Indicator 
Zellerino et al. (2009) Internal Consistency 
Decision Evaluation Scale  Stalmeier et al. (2005) Internal Consistency 
Content Validity 
Construct Validity 
Decisional Conflict Scale (DCS)  O’Connor (1995) Internal Consistency 
Retest Reliability 
Construct Validity 
Criterion Validity 
Decision making process  Brain et al. (2005); Michie et 
al. (1997) 
Internal Consistency 
Desire to participate in the program Stalmeier et al. (1999) Internal Consistency 
Emotional reaction to the program Stalmeier et al. (1999) Internal Consistency 
Evaluation of practical issues and 
responsibilities 
Otten et al. (2016) Content Validity 
Expectations of online counselling Otten et al. (2016) Content Validity 
Family Environment Scale (FES)  
 
 
Moos & Moos (1994) 
Halvorsen (1991) 
Internal Consistency 
Retest Reliability  
Face Validity 
Content Validity 
Construct Validity 
Functional Assessment of Cancer 
Therapy-General (FACT)  
Cella et al. (1993) 
Brady et al. (1997) 
Internal Consistency 
Retest Reliability 
Construct Validity 
Sensitivity 
General Health Questionnaire (GHQ)  Goldberg & Williams (1988).  
Goldberg & Hillier (1979) 
Internal Consistency 
Retest Reliability 
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Content Validity 
Construct Validity 
Criterion Validity 
Interpretability 
Sensitivity 
Genetics Appointment Patient Satisfaction 
Score (GAPPS) 
Westwood et al. (2012) Content Validity 
The Genetic Counseling Outcome Scale 
(GCOS-24) 
McAllister et al. (2011b) Internal Consistency 
Face Validity 
Content Validity 
Construct Validity 
Retest Reliability 
Sensitivity 
Genetic Counseling Satisfaction Scale 
(GCSS)  
Tercyak et al. (2001) Internal Consistency 
Face Validity 
Genetic Knowledge Index (GKI)  Furr & Kelly (1999) Internal Consistency 
Construct Validity  
Global Severity Index (GSI) of the 
Symptom Check List-90 (SCL90)  
Derogatis (1983) Internal Consistency 
Retest Reliability 
Construct Validity 
Criterion Validity 
Sensitivity 
Health Beliefs Model Kash et al. (1992) Face Validity 
Health Orientation Scale  
 
Woolridge & Murray (1989) Internal Consistency 
Retest Reliability 
Construct Validity 
Hopkins Symptom Checklist (HSCL)  Derogatis et al. (1974) Internal Consistency 
Retest Reliability 
Construct Validity 
Criterion Validity 
Hospital Anxiety and Depression Scale 
(HADS)  
Zigmond & Snaith (1983) Internal Consistency 
Content Validity 
Illness Perception Questionnaire (IPQ) Cho et al. (2012) Content Validity 
Impact of Event Scale (IES)  Horowitz et al. (1979) Internal Consistency 
Retest Reliability  
Sensitivity 
Intention to act upon program  Stalmeier et al. (1999) Internal Consistency 
Knowledge About Breast Cancer  Donovan & Tucker (2000) 
Stager (1993) 
Vaeth (1993) 
Internal Consistency 
Content Validity 
Knowledge about genetic testing for 
inherited cancer  
Lerman et al. (1996) Internal Consistency 
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Knowledge about genetic risk for breast 
cancer  
Donovan & Tucker (2000) Internal Consistency 
Knowledge Scale about Breast (and 
Ovarian) Cancer and Hereditary 
Ondrusek et al. (1999) Retest Reliability 
Content Validity  
Life Orientation Test (LOT)  
 
Scheier et al. (1994) 
Carver et al. (1994) 
Internal Consistency 
Retest Reliability 
Construct Validity 
Measure of Counselees’ Knowledge of 
Down Syndrome  
Braitman & Antley. (1978) Face Validity 
Content Validity 
Internal Consistency 
Medical Communication Behaviour 
System (MCBS)  
 
Wolraich et al. (1986) Content Validity 
Construct Validity 
Criterion Validity 
Medical Interview Satisfaction Scale - 
modified (MISS)  
Wolf et al. (1978) Internal Consistency 
Content Validity 
Medical Outcomes Short-Form Survey 
(SF-36 and SF-12) 
Ware (1993) 
Jenkinson et al. (1996) 
Internal Consistency 
Content Validity 
Criterion Validity 
Construct Validity 
Medical Outcomes Study Social Support 
Scale (MOSS)  
Sherbourne et al. (1991) Internal Consistency 
Retest Reliability 
Construct Validity 
Miller Behavioural Style Scale Miller (1987) Internal Consistency 
Retest Reliability 
Minnesota Multiphasic Personality 
Inventory (MMPI) 
 
Graham (1987) Internal Consistency 
Retest Reliability 
Content Validity 
Construct Validity 
Criterion Validity  
Modified Maternal Serum Screening 
Knowledge Questionnaire (MSSKQ)  
Goel et al. (1996) Internal Consistency  
modified Tolerance for Ambiguity Scale 
(TFA)  
Geller et al. (1993) Internal Consistency 
Content Validity 
Multidimensional Impact of Cancer Risk 
Assessment (MICRA)  
 
Cella et al. (2002) Internal Consistency 
Construct Validity 
Criterion Validity 
Openness to Discuss Cancer in the Family 
Scale (ODCFS)  
Mesters et al. (1997) Internal Consistency 
Content Validity 
Criterion Validity  
Patient Health Questionnaire (PHQ-9) Meiser et al. (2013) Content Validity 
Patient Satisfaction with Genetic Brain et al. (2000); Shiloh et al. Internal Consistency 
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Counselling (1990) 
Penn State Cancer Genetics Program 
Survey 
Kausmeyer et al. (2006) Content Validity 
Perceived Devaluation Discrimination 
Scale (PDDS) 
Meiser et al. (2013) Internal Consistency 
Perceived personal control (PPC)  Berkenstadt et al. (1999) 
Otten et al. (2016) 
Internal Consistency 
Construct Validity 
Content Validity 
Sensitivity 
Perceived Risk of Breast Cancer Brain et al. (1999) Internal Consistency 
Perceptions of the benefits, limitations and 
risks of genetic testing 
Donovan & Tucker (2000); 
Hughes et al. (1997) ; Audrain 
et al. (1995) 
Internal Consistency 
Pharmacogenetics in Psychiatry follow-up 
questionnaire (PIP-FQ) 
Walden et al. (2015) Internal Consistency 
Profile of Mood State (POMS)  
 
McNair et al. (1981) Internal Consistency 
Retest Reliability 
Face Validity 
Prostate cancer genetic screening survey  Doukas (2004) Internal Consistency 
 
Psychological Adaptation to Genetic 
Information Scale (PAGIS)  
Read et al. (2005) Internal Consistency 
Content Validity 
Psychological Consequences 
Questionnaire (PCQ) 
 
Cockburn et al. (1992) Internal Consistency 
Content Validity 
Construct Validity 
Quality of Care Through the Patients’ 
Eyes (QUOTE)-geneCA 
 
Pieterse et al. (2005) Internal Consistency 
Content Validity 
Construct Validity 
Risk comprehension and subjective 
knowledge  
Stalmeier et al. (1999) Internal Consistency 
Rosenberg Self-Esteem Scale  Rosenberg (1965) 
Curbow & Somerfield (1991) 
Internal Consistency 
Retest Reliability 
Satisfaction with Decision Scale  
 
Brain et al. (2005) 
Holmes-Rovner et al. (1996) 
Internal Consistency 
Satisfaction with Genetic Counselling 
Questionnaire 
Hilgart et al. (2012) Content Validity 
Satisfaction with shared decision making 
program  
Stalmeier et al. (1999) Internal Consistency 
Construct Validity 
Self-rating Depression Scale (SDS)  Zung (1965) Internal Consistency 
Content Validity 
Face Validity 
Construct Validity 
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Shared decision making program 
rationale acceptability  
Stalmeier et al. (1999) Internal Consistency 
Short-form Health Survey (SF-12) Hubalek et al. (2016) Internal Consistency 
Retest Reliability 
Face Validity 
Content Validity 
Construct Validity 
Short-form Health Survey (SF-36) Bowen & Powers (2010) Internal Consistency 
Retest Reliability 
Face Validity 
Content Validity 
Construct Validity 
Spielberger State Trait Anxiety Inventory 
(STAI) and state scale (STAI-State)  
 
 
 
Spielberger et al. (1970) 
Marteau & Bekker (1992) 
Internal Consistency 
Retest Reliability 
Face Validity 
Content Validity 
Construct Validity 
Criterion Validity 
Sensitivity 
Interpretability 
Spiritual Well-Being Scale (SWBS)  Ellison & Smith (1991) 
Gioiella et al. (1998) 
Internal Consistency 
Retest Reliability 
Criterion Validity 
Subjective Quality of Life Profile (SQLP)  Dazord (1995) Internal Consistency 
Retest Reliability 
Criterion Validity 
Construct Validity 
Telemedicine Satisfaction Questionnaire 
(TSQ) 
Otten et al. (2015) Internal Consistency 
Tennessee Self-Concept Scale  Fitts (1965) Internal Consistency 
Retest Reliability 
Construct Validity  
Criterion Validity 
Utrecht Coping List (UCL)  Westbrook (1979) Internal Consistency 
Worry Interference Scale (WIS) Trask (2001) Internal Consistency 
Retest Reliability 
Content Validity 
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Table 2.3 Definitions of scale psychometric properties. 
Content Validity A non-statistical assessment of whether the measure covers the totality 
of the underlying theoretical construct. 
Concurrent Validity The extent to which the results of a test correspond to those of a 
previously established test for the same construct. 
Construct Validity The extent to which a measure captures the underlying theoretical 
construct. 
Criterion Validity The extent to which a measure is related to an outcome, i.e. the 
correlation between a test and an outcome. 
Face Validity The degree to which a scale appears effective with respect to its aim. 
Internal Consistency The degree of correlation between items in a scale. Indexed using 
Cronbach’s alpha. 
Interpretability Assigns a numerical value to represent the degree to which a meaning is 
derived from a term, item or measure. Usually assessed using minimal 
important change (MIC) or minimal important difference (MID). 
MIC / MID The smallest change in a PRO that patients perceive as important. See 
interpretability 
Preference-based Reflecting the value or priority which is placed on each item by the 
target population. This allows changes in health state to be interpreted. 
Responsiveness / 
Sensitivity to Change 
Also called ‘responsiveness’. The ability of an instrument to accurately 
assess change in the measured construct. 
Test-Retest 
Reliability 
The degree to which the test produces consistent results over two time 
periods. 
 
  2.3.4 Results Summary 
In summary, this literature review identified 82 validated outcome measures used in 
the evaluation of CGS. A variety of different domains are captured by these measures, 
but many only pertain to a specific outcome and so represent a limited perspective of 
what CGS can offer patients. The Audit Tool for Genetics Services (Skirton et al., 2005), 
the Perceived Personal Control (PPC) questionnaire (Berkenstadt et al., 1999), and the 
Genetic Counselling Outcome Scale (GCOS-24) (McAllister et al., 2011b) are the only 
instruments which capture a range of potential CGS patient outcomes. Additionally, the 
extent of psychometric validation was often low, with approximately one quarter being 
assessed for internal consistency alone. The results will now be discussed. 
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2.4  Discussion 
This literature review has identified 82 validated outcome measures, either developed 
or used in the evaluation of CGS. Generic measures of physical health status were not 
commonly used, which is not surprising given that interventions offered by CGS are 
generally not able to provide physical health benefits. A small number of studies, 
however, utilised the generic Short-form Health Survey (SF-36) and the reduced 
version SF-12 to measure health status in the context of cancer genetics. Hubalek et al. 
(2016), for example, included SF-12 in a bundle of seven PROMs sent out to patients in 
order to investigate the long-term psychosocial consequences of genetic counselling 
and testing for hereditary breast and ovarian cancer. Bowen & Powers (2010) included 
SF-36 as part of a before-and-after study, in which six separate measures were applied 
to gather data on cancer worry, estimated risk for breast cancer, quality of life, 
knowledge of breast cancer, and awareness and perception of genetic testing. Items 
common to both SF-36 and SF-12 include: ‘In general, would you say your health is...’ 
(Excellent – Poor) and ‘Does your health now limit you in climbing several flights of 
stairs?’ (Yes, a lot – No, not limited at all). All studies in this review which utilised a 
generic health measure did so in conjunction with other measures, emphasising the 
fact that generic health measures are not sufficient to capture CGS outcomes. Indeed 
the majority of outcomes measures used to evaluate CGS capture Health-Related 
Quality of Life (HRQoL) outcomes, including the physical, emotional, psychological, and 
social domains of health. 
Almost half of the instruments refer to genetics or a genetic condition. An example of a 
genetics-specific instrument is Erblich et al.’s Breast Cancer Genetic Counselling 
Knowledge Questionnaire (BGKQ) (Erblich et al., 2005), a 27-item instrument 
developed with the aim of assessing women’s knowledge of information presented 
during breast cancer genetic counselling. Some items are scored using a True / False / I 
don’t know system, e.g. ‘50% of inherited genetic information (about breast cancer 
risk) is passed down from a person’s mother’ and ‘One in 10 women has a breast 
cancer gene mutation’, and some items offer multiple choice, e.g. ‘What is the 
approximate risk that the average woman in the United States will develop breast 
cancer in her lifetime? (a. 12%; b. 24%; c. 58%; d. 72%; e. I don’t know)’. One of the 
benefits of genetics-specific measures is that they have often been designed to include 
specialised items, capturing distinct outcomes relevant to the intended context. If the 
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specialised items are condition-specific, however, as with the BGKQ, the wider 
application of the instrument in CGS is limited. 
Aside from the generic health measures, the majority of non-genetics-specific 
measures were used to capture a singular outcome domain, known to be relevant in 
the context of CGS. The revised Life Orientation Test (Scheier et al., 1994), for example, 
is a ten-item measure of optimism versus pessimism. Respondents are asked to 
designate their level of agreement (‘I agree a lot’ to ‘I disagree a lot’) with items such as 
‘It’s easy for me to relax’ and ‘I’m always optimistic about my future’. The 20-item 
Medical Outcomes Study (MOS) Social Support Survey (Sherbourne & Stewart, 1991) 
was designed to comprehensively assess various dimensions of social support. A five-
point Likert scale ranging from ‘None of the Time’ to ‘All of the Time’ is presented, with 
items including ‘How often would someone be able to help you if you were confined to 
bed?’ and ‘How often does someone show you love and affection?’. Any measure 
intended for use in CGS evaluations should capture a range of potential patient 
outcomes provided by the service. 
In summary, generic measures of health will likely not be appropriate in the context of 
CGS. Both genetics-specific and non-genetics-specific instruments were identified 
which measure relevant HRQoL outcomes, but if an instrument is to be used as a 
universal PROM in CGS it must be applicable to all potential CGS patients and must 
capture a range of potential patient outcomes. 
 
2.4.1  The Narrow Scope of Existing Measures  
The majority of measures identified in this study are designed to capture a specific 
outcome or a restricted number of outcomes. Common outcome domains include 
patient knowledge regarding the condition, patient satisfaction with the genetic 
counselling process, anxiety and depression. Whilst such measures may be valid and 
robust, and highly relevant in specific contexts, they fail to take into account the range 
of potential benefits that CGS can offer. The Psychological Consequences 
Questionnaire (PCQ), for example, was developed by Cockburn et al. (1992) to assess 
the consequences of breast mammography on well-being. It contains 12 items, each 
rated on a four-point scale with options ranging from ‘not at all’ to ‘quite a lot of the 
time’, and respondents are instructed to indicate how often they had experienced 
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social, physical, and emotional reactions in the previous week as a result of concerns 
about breast cancer (e.g. ‘have you experienced a change in appetite’; ‘have you been 
scared or panicky’; and ‘have you felt worried about your future’). The instrument has 
good construct validity, concurrent validity and internal consistency, and has since 
been used in subsequent studies examining emotional well-being in women receiving 
counselling for breast cancer risk (Kent et al., 2010; Rijnsburger et al., 2006). As a 
universal PROM for CGS evaluations, the PCQ is too specific to be suitable. 
A number of measures were specifically designed to capture depression, for example 
the Self-rating Depression Scale (SDS) (Zung, 1965), the Beck Depression Inventory (Su 
et al., 2009), and the Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983). 
The 20-item SDS was constructed for the purpose of assessing the physiological and 
psychological symptoms of depression, and contains items such as: ‘I feel downhearted 
and blue’; ‘I have trouble sleeping at night’; and ‘I am more irritable than usual’ (Zung, 
1965). Respondents are asked to select one of four options from ‘A Little of the Time’ 
to ‘Most of the Time’. Depression is certainly relevant in the context of CGS, with 
several studies indicating that a substantial proportion of individuals seeking genetic 
counselling for hereditary cancer have high levels of anxiety and depression (Geirdal et 
al., 2005; Reichelt et al., 2004; Schlich-Bakker et al., 2006). Genetic counselling has also 
been shown to reduce depression levels in individuals at risk for hereditary cancer 
(Bjorvatn et al., 2008). None of the measures of depression identified in this review, 
however, are sufficient to evaluate the complex range of potential patient benefits 
from CGS. 
Patient knowledge is another important element of genetic counselling and a valuable 
outcome in the eyes of the NHS. Indeed in Resta et al.’s (2006) definition for the 
speciality it states that genetic counselling integrates ‘Education about inheritance, 
testing, management, prevention, resources and research’ (p77). In 1989, information 
giving was listed by the NHS during their proposed reforms, stating that hospitals 
should offer patients ‘clear and sensitive explanations of what is happening, on 
practical matters such as where to go and who to see, and on clinical matters such as 
the nature of an illness and its proposed treatment’ (DoH, 1989, paragraph 1.13). 
The measures of knowledge used to date have mainly been specific to a certain 
condition. The ‘Measure of Counselees’ Knowledge of Down Syndrome’ constructed by 
Braitman & Antley (1978), for example, is a 26-item test with items such as: ‘What are 
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the chances that the brother or sister of a person with Down syndrome will have a 
baby with Down syndrome?’ and ‘Children with Down syndrome always have an extra 
chromosome or an extra piece of a chromosome (True / False)’. Similarly, the ‘Risk 
Comprehension and subjective knowledge’ test used by Stalmeier et al. (1999) is 
specific to breast cancer. An example item reads, ‘What percentage of women (average 
women in the general population) get breast cancer before the age of 70?’ The wider 
application of these condition-specific measures is limited. Additionally, using 
measures of knowledge or information recall to evaluate CGS can be problematic. The 
value placed on certain pieces of information will vary from person to person, as will 
the interpretation of information, particularly risk figures (Clarke et al., 1996). Several 
findings also indicate that educational or informational elements of genetic counselling 
provide fewer benefits and are relatively less important to CGS users than supportive 
or emotional elements (Bowen et al., 2004; Lerman et al., 1997; Edwards et al., 2008). 
Twelve PROMs were designed to capture patient satisfaction. This may be satisfaction 
with the genetic counselling process (Otten et al., 2016), satisfaction with a medical 
decision (Holmes-Rovner et al., 1996), or satisfaction with respect to quality of life 
(Ellison & Smith, 1991). The wider literature suggests that CGS patients are generally 
highly satisfied with the service, finding genetic counselling to be informative and 
helpful (Bleiker et al., 1997; DeMarco et al., 2004; Nordin et al., 2002; Sagi et al., 1998; 
Schneider et al., 1999; Shiloh et al., 1990; Stadler & Mulvihill, 1998; Veach et al., 1999). 
Patient satisfaction, however, may be dependent on a number of factors, and it is often 
not clear what aspects of the service are driving satisfaction levels. Bernhardt et al. 
(2000) found that one of the things the majority of clients liked most about their 
genetic counselling experience was their genetic counsellor, and clients spent a 
considerable amount of time during the follow-up interviews talking about how well 
they ‘connected’ with their counsellor. In contrast, the information provided to 
patients regarding a condition may cause significant distress. Whilst it is important to 
measure CGS outcomes from the patients’ perspective, global patient satisfaction 
levels are not widely seen as a suitable metric for success in CGS (Clarke et al., 1996, 
Payne et al., 2008). Attention must instead be focused upon specific elements of the 
service, for example in Stalmeier et al.’s (1999) Satisfaction with the Shared Decision 
Making Program (SDMP) scale. Items include, ‘Did the SDMP give you more/less insight 
in the treatment choice?’ and ‘Did the SDMP enable you to discuss your problem 
better/worse with others?’  
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Of the 82 instruments identified in this review, only three incorporate a range of 
outcome domains relevant to CGS: The Audit Tool for Genetics Services (Skirton et al., 
2005), GCOS-24 (McAllister et al., 2011b), and the PPC questionnaire (Berkenstadt et 
al., 1999). The 18-item Audit Tool was the result of a study aiming to develop a 
practical research and audit tool to measure outcomes of CGS (Skirton et al., 2005). 
The questionnaire addresses six outcome domains (with example items in parenthesis): 
(i) Enhanced understanding (‘I have more understanding of what causes the 
condition’); (ii) Positive psychological change (‘I feel more positive’); (iii) Respect for 
autonomy (‘My main questions were answered’); (iv) Adaptation (‘I feel I can adapt 
better to changes’); (v) Disequilibrium (‘I did not feel comfortable’); (vi) Value of 
contact (‘I felt treated as an individual’). Responses are assessed on a seven-point 
Likert scale ranging from ‘totally agree’ to ‘totally disagree’. However, for a health 
measurement scale to be suitable for use in service evaluation it must be sensitive to 
change. Due to item wording, The Audit Tool can only be used post-counselling, and is 
therefore unable to measure pre/post change. 
The concept of PPC, established by Averill (1973) to reflect the extent to which a 
person believes that they are in control of a situation and that they are able to bring 
about positive changes to the situation, was operationalised as a measure for genetic 
counselling by Berkenstadt et al. (1999). The instrument captures a range of outcomes 
in genetic counselling, asking counselees their subjective perceptions of how much 
control they believe they have with regard to their genetic problem. More specifically, 
the PPC scale contains nine items representing three dimensions of control: Cognitive 
Control (e.g. ‘I think I understand what problem brought me to genetic counselling’); 
Behavioural Control (e.g. ‘I feel I know what to do to ease the situation’); and 
Decisional Control (e.g. ‘I feel I have the tools to make decisions that will influence my 
future’). The PPC scale is valid, reliable, and responsive to change pre/post genetic 
counselling, and has been shown to be highly relevant as a patient reported outcome, 
valued by both patients and genetics clinicians (Payne et al., 2007; McAllister et al., 
2012). Great Ormond Street Hospital, in their most recent biennial CGS questionnaire, 
used an adapted version of the PPC measure to evaluate CGS, with results suggesting 
that CGS appointments improve patients’ understanding of what the genetic condition 
means for them and their families, as well as patients’ sense of confidence in having 
the information to make choices. 
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GCOS-24 (McAllister et al., 2011b) is a 24-item questionnaire which captures 
empowerment (Table 2.4) (McAllister et al., 2011a). Empowerment includes all three 
PPC dimensions, as well as two further dimensions, Hope and Emotional Regulation, 
which represent elements such as anxiety, guilt, and hope for the future. It was 
developed through extensive qualitative research with genetics clinicians and those 
affected by having a genetic condition in the family. In an initial study, seven focus 
groups and 19 interviews were conducted with patients, patient group representatives, 
and health professionals (McAllister et al., 2008). Following on from this, 
empowerment was validated and refined through further qualitative research with 12 
patients, 15 representatives from patient support groups, 10 genetics clinicians and 4 
service commissioners (McAllister et al., 2011a). GCOS-24 has been shown to have a 
high degree of clinical utility, being used for service evaluation (Inglis et al., 2014; 
McAllister et al., 2016) and quality improvement (Costal-Tirado et al., 2017) in CGS. It 
has also received international attention, being translated into Danish (Diness et al., 
2017) and Spanish (Munoz-Caballo et al., 2017). 
 
Table 2.4: Empowerment. (McAllister et al. 2011a). 
Empowerment 
Dimension 
Definition (The belief that one...) 
Cognitive Control ...has sufficient information about the condition, including 
risks to oneself and one’s relatives, and any treatment, 
prevention and support available. 
Decisional Control ...can make important life decisions in an informed way. 
Behavioural Control ...can make effective use of the health and social care 
systems 
Emotional Regulation ...can manage their feelings about having a genetic condition 
in the family 
Hope ...can look to the future having hope for a fulfilling family life, 
for oneself, one’s family, and/or one’s future descendents 
 
In summary, the majority of measures identified in this review encompass only a 
narrow scope of potential patient outcomes which CGS can provide. Frequently 
observed outcome domains included patient knowledge, patient satisfaction, and 
depression, but each only represents a certain element within the complex array of 
CGS outcomes. Additionally, objective measures of information recall and of 
satisfaction can be problematic when used as indicators of service quality or patient 
Page 35 of 116 
 
benefit. The 9-item PPC and the 24-item GCOS-24 both capture multi-dimensional 
constructs, incorporating outcomes relating to ‘Cognitive Control’, ‘Decisional Control’, 
and ‘Behavioural Control’. GCOS-24 goes even further, including ‘Emotional Regulation’ 
and ‘Hope’ (Table 2.4).  Extensive qualitative research suggests that these outcomes 
are relevant and valued by CGS users, and both instruments have a high degree of 
clinical utility. 
 
  2.4.2 The Heterogeneity of Existing Measures 
The results from this review demonstrate a noticeable lack of consensus over the best 
way to evaluate patient outcomes from CGS, a sentiment echoed by other authors 
(Clarke et al., 1996; McAllister et al., 2008; McAllister & Dearing, 2015; Munoz-Cabello 
et al., 2018; Payne et al., 2008; Wang et al., 2004). Indeed the high degree of 
heterogeneity in outcome measures has been identified as being a principal 
methodological limitation in reviews of economic evaluations in CGS, causing 
difficulties when making comparisons and drawing conclusions (Carlson et al., 2005; 
Djalalov et al., 2011). In a recent review of evaluations of predictive genetic testing 
programs (D’Andrea et al., 2015), the variety of results produced by the various 
outcome measures was such that results could not be pooled and statistical methods 
could not be applied; a descriptive approach was taken instead. 
Over half of the measures identified in this review were used in the evaluation of CGS 
for inherited cancers, primarily breast cancer. Many instruments were developed for 
use in a specific study, and would not be applicable in any other context. In Kausmeyer 
et al. (2006), for example, the aim of the study was to explore patient expectations, 
experiences and satisfaction with the Penn State Cancer Genetics Program, and a 
bespoke survey was developed accordingly. ‘The Penn State Cancer Genetics Program 
Survey’ contains 80 multiple choice items, including: ‘How did you hear about the Penn 
State Cancer Genetics Program?’ and ‘Did the Cancer Genetics Packet and appointment 
letter mailed prior to your visit provide useful information regarding the cancer risk 
assessment process?’ Similarly, Stalmeier et al. (1999) composed a number of novel 
bespoke measures to evaluate a Shared Decision Making Program (SDMP) for women 
suspected to have a genetic predisposition to breast cancer. Outcome domains 
included desire to participate in the SDMP, satisfaction with the SDMP, and the 
intention to act upon the SDMP, with items such as ‘Did the SDMP give you more/less 
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insight in the treatment choice?’ and ‘Imagine that a close friend would have a high risk 
for breast cancer. Would you recommend the SDMP?’ Instruments such as these are 
bound by their wording to be relevant only in a specific context, and comparisons with 
other instruments are difficult if not unworkable. 
Two instruments studied outcomes from the perspective of the physician, the modified 
Tolerance for Ambiguity Scale (Geller et al., 1993) and the Pharmacogenetics in 
Psychiatry Follow-up Questionnaire (PIP-FQ) (Walden et al., 2015). The PIP-FQ was 
designed to assess physicians’ perceptions of pharmacogenetic testing and their 
experience using the test results. Items include ‘Has the information been easy to 
understand?’ and ‘Based on your experience, would you refer additional patients into 
our study?’ Evaluating CGS from the perspective of the provider is not considered to be 
best practice (Clarke et al., 1996). In a study by Wertz et al. (1988), patient outcomes as 
judged by the provider appeared to be associated with the education level of the 
patient rather than whether the needs of the patient had been met. Bernhardt et al. 
(2000) describe the idea of counsellor expectations influencing their perception of 
patient outcomes, saying that some counsellors expect their counsellees to show some 
level of engagement, and are often dissatisfied if there is a reduced level of response. 
From the patient’s perspective, a reduced response may simply mean that they are 
listening and taking in the information they have been given.   
In the absence of a universal instrument, a number of studies evaluating CGS chose to 
adapt an existing measure rather than develop a novel one. Van Oostrum et al. (2003) 
adapted the Openness to Discuss Cancer in the Family Scale originally constructed by 
Mesters et al. (1997) to assess the impact of genetic testing for cancer susceptibility on 
family relationships; Bowen et al. (2002) modified certain questions from the Tolerance 
for Ambiguity Scale (Geller et al., 1993), as well as certain questions from a scale 
measuring fear of stigma associated with cystic fibrosis, for use in the context of breast 
cancer. The extent of scale adaptation varied from study to study, but as a whole this 
practice emphasises the lack of harmony regarding measurement scales in the context 
of CGS. 
Having a suitable PROM accepted as the standard in CGS will enable patient outcomes 
to be compared and contrasted between separate interventions. It will help to identify 
which services are effective and of value, to encourage common practice, and to 
provide robust evidence for audit and service development. This was emphasised by 
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the National Institute for Clinical Excellence (NICE) in 2004, who called for the 
establishment of generic outcome measures to allow separate interventions to be 
compared directly (NICE, 2004). Ultimately, a standard measure will help to ensure that 
CGS patients are receiving optimal medical care.  
Of the three measures designed to capture a range of outcome domains from CGS (The 
Audit Tool (Skirton et al., 2005); PPC (Berkenstadt et al., 1999); GCOS-24 (McAllister et 
al., 2011b)) only the PPC and GCOS-24 were identified in more than one study. GCOS-
24 is of particular note, since it was created with the intention of filling the gap 
generated by the lack of a universal PROM within CGS (McAllister et al., 2011b). 
Despite being developed relatively recently, it has gone on to be used in multiple 
studies, both within the UK and internationally (Costal-Tirado et al., 2017; Diness et al., 
2017; Munoz-Caballo et al., 2017). 
 
 
  2.4.3 The Limited Validation of Existing Measures 
Internal consistency, test-retest reliability and validity (Table 2.3) are essential 
properties for any measurement scale (Aaronson et al., 2002; Mokkink et al., 2010). 
The 2010 Consensus-based Standards for the selection of health measurement 
instruments (COSMIN) checklist, which provides guidelines for assessing the 
methodological quality of measurement scales, also describes how content validity, 
construct validity, responsiveness and interpretability are also relevant criteria to be 
considered when assessing a measurement scale (Mokkink et al., 2010). Many of the 
measures identified in the review had undergone limited psychometric evaluation, 
with over half being assessed for internal consistency alone. For the purposes of this 
review any form of validation was sufficient for inclusion, but it could be argued that 
internal consistency alone is not sufficient evidence to confirm a measure as validated. 
Since the calculation is based upon item correlations, random error averages out as 
one adds more items, so in practice scales over 20 items generally have acceptable 
values of α (>.7) (Streiner, 2003). Shorter scales will have fewer correlations from  
which to draw upon and in turn may present with lower values. Cronbach’s α, the 
index for internal consistency, would be higher for a 20-item measure with a mean 
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inter-item correlation of 0.1, than for a 5-item measure with a mean inter-item 
correlation of 0.3. 
Traditional psychometric tests such as internal consistency and test-retest reliability fall 
into a category of tests known as Classical Test Theory (CTT). CTT approaches have 
guided the construction, refinement and validation of measurement scales for 
decades, and continue to remain the dominant paradigm (Petrillo et al., 2015). There 
are, however, some issues with CTT that concern the calibration of item difficulty, 
sample dependence of coefficient measures, and estimates of measurement error 
(Magno, 2009). In short, CTT is a theory about test scores that introduces three 
concepts: (i) test score, often called the observed score (TO); true score (T), and error 
score (E), where the true and error scores are independent. These variables within CTT 
are best illustrated in the formula: TO = T+E. Because for each examinee there are two 
unknowns to the equation, some simplifying assumptions are made. The assumptions 
in the CTT model are that: (a) true scores and error scores are uncorrelated; (b) the 
average error score in the population of examinees is zero; (c) error scores on parallel 
tests are uncorrelated. In other words, the theory starts from the assumption that 
systematic effects between test responses are due only to variation in the ability of 
interest; all other potential sources of variation existing in the testing materials such as 
external conditions are assumed either to be constant or to have an effect that is 
random by nature (Linden & Hambleton, 2004). In other formulations of this model 
(e.g. Lord & Novick, 1968), true score is defined as the expected test score over parallel 
forms, and then the resulting properties of the error are derived.  
Advantages of many CTT models are that they are based on relatively weak 
assumptions (i.e. they are easy to meet in real test data), and they are well known and 
have a long track record. On the other hand, both person parameters and item 
parameters are dependent on the test and the examinee sample, respectively, and 
these dependencies can limit the utility of the person and item statistics in practical 
test development. 
Item Response Theory (IRT) is a relatively recent approach to psychometric design, 
developed to overcome the problems with CTT approaches (Wiberg, 2004). In IRT, it is 
assumed that an examinee has some latent unobservable trait (also called ability), 
which cannot be studied directly. The purpose of IRT is to propose models that permit 
to link this latent trait to some observable characteristics of the examinee. According 
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to Sohn (2009), one of the distinguishing characteristics of item indices under CTT and 
IRT frameworks is whether they are sample dependent or invariant. Whereas in CTT 
one uses a common estimate of the measurement precision that is assumed to be 
equal for all individuals irrespective of their ability level, in IRT the measurement 
precision depends on the ability (latent trait) value. As a result, IRT models will 
theoretically produce item statistics which are independent of examinee samples, and 
person statistics independent of the particular set of items administered. This 
invariance property of item and person statistics of IRT has been illustrated by 
Hambleton & Swaminathan (1985); Hambleton, Swaminathan and Rogers (1991). 
The calculations involved in IRT models also make them preferable to CTT when 
analysing ordinal responses; e.g. Likert rating scales. For although the response 
categories in Likert scales have a rank order, it is not necessarily correct to presume 
that the intervals between values are equal. By way of example, would the ‘difference’ 
between Disagree and Strongly Disagree be the same as that of Agree and Strongly 
Agree? Treating ordinal scales as interval scales has long been controversial, and the 
subjective and ordinal nature of Likert scale data has proven problematic for formal 
statistical analysis (Jamieson, 2004). IRT methods were specifically developed to 
address the issue of subjective ordinal responses and the need to create robust 
measures. 
Thus, IRT has been considered to hold a number of advantages over CTT, and from a 
practical perspective IRT methods can greatly assist in the construction and refinement 
of PROMs (Hays et al., 2000; Nguyen, 2014). Indeed they are already being applied to 
some of the major PROMs, such as the EQ-5D, HUI2, HUI3, and SF-6D (Fryback et al., 
2009; Gibbons et al., 2014; Johnsen et al., 2013; van Hout et al., 2012). No measure 
included in this review was developed using IRT, and no study utilised IRT. 
Only six measures identified in this review have been assessed for sensitivity. Both PPC 
and GCOS-24 are well-validated in this respect, as well as for internal consistency, test-
retest reliability and content validity (McAllister et al., 2011b; McAllister et al., 2012; 
Berkenstadt et al., 1999). Neither instrument, however, has been studied for 
interpretability, which is not unusual since only two of the 82 have (STAI (Spielberger et 
al., 1970); GHQ (Goldberg & Hillier, 1979)).  
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  2.4.4  Valuing Health States: Preference weights 
Over recent years, national decision-making bodies in the UK involved in the appraisal 
of cost-effectiveness of healthcare interventions have called for outcome measures 
used in service evaluation to be ‘preference based’ (NICE, 2004). A preference-based 
measure is a measure of HRQoL that has a set of ‘preference weights’ which reflect the 
value that individuals attach to each item and response option. This allows more 
desirable outcomes to receive greater weight in the analysis, and enables changes in 
score to be interpreted. 
Nowadays, preference-based measures are being widely used in health economic 
evaluations and health technology assessments (HTA) within the UK system. Indeed 
there is in fact a dedicated HTA programme, funded by the NHS, which utilises 
preference-based measures to examine the clinical effectiveness, the cost 
effectiveness, and the broader impact of healthcare treatments. ‘Health technologies’ 
are broadly defined as all interventions used to promote health, prevent and treat 
disease, and improve rehabilitation and long-term care. 
The EQ-5D (Brooks, 1996), for example, is a preference-based measure of health, 
widely used in cost-effectiveness analysis. The five items relate to domains of mobility, 
self-care, pain/discomfort, usual activities, and anxiety/depression, and there are three 
levels of severity: ‘no problems’, ‘some problems’, and ‘severe problems’. Each 
response pattern has a preference weight attached, and such is the popularity of the 
EQ-5D that many separate countries have assigned their own preference weights 
(Badia et al., 2001 (Spain); Goudarzi et al., 2016 (Iran); Lamers et al., 2006 
(Netherlands); Lee et al., 2013 (Taiwan); Wu et al., 2016 (China)). 
None of the measures identified in this literature review are preference-based. If a CGS 
intervention were to be appraised by NICE, no instrument would meet their suggested 
requirements. With generic measures of health being of limited applicability in CGS, 
the lack of a relevant preference-based measure is seriously impeding rigorous audit of 
the service and comparison of different models of service delivery. 
 
 2.5 Limitations 
One limitation of this review was the exclusion of non-validated outcome measures. 
This was a practical decision since validated measures are required for robust 
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evaluations, but may have resulted in potentially relevant instruments being excluded. 
Additionally, it could be argued in some studies that non-statistical properties such as 
face validity or content validity were implied. Thompson et al. (2015), for example, 
developed a five-item survey to examine psychiatrist attitudes towards 
pharmacogenetic testing and integrating genetic counselling into psychiatric patient 
care. Over 100 surveys were completed by practicing psychiatrists, with results strongly 
indicating that genetic data would be useful in making pharmaceutical decisions. Due 
to time constraints the measure was not piloted, and no validation was reported, but 
the process of construction and subsequent relevance implies face and content 
validity. 
Determining scale validity was not always a straightforward process, particularly with 
adapted scales. A purist approach would require any changes to a scale to be 
separately validated, but for the purposes of this review a more flexible, inclusive 
approach was taken. Therefore not all reported scales were uniquely validated in their 
own right. The inclusion of a second reviewer during the screening process would have 
been beneficial. A further limitation is that only studies reported in English were 
included. 
 
2.6  Refined Research Problem and Study Aims 
GCOS-24 (Figure 2.1) emerged from the literature review as being the outstanding 
candidate for routine use in audit and clinical evaluations of CGS. GCOS-24 items are 
grounded in extensive qualitative research with CGS patients and providers, and the 
measure has been demonstrated to be valid, reliable and responsive, with no floor or 
ceiling effects observed (McAllister et al., 2011b). GCOS-24 has previously been used 
for service evaluation (Inglis et al., 2015; McAllister et al., 2016) and quality 
improvement (Costal-Tirado et al., 2017) in genetic counselling services, and it has also 
received international attention, having been translated into Danish (Diness et al., 
2017) and Spanish (Munoz-Caballo et al., 2018). Perhaps most importantly, GCOS-24 
captures a range of patient outcome domains from CGS. 
However, if GCOS-24 is to meet NICE requirements for use in cost-effectiveness and 
HTA evaluations, it must have preference-weights attached. At a present length of 24 
items each with 7 response options, GCOS-24 produces a substantial number of 
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possible response permutations (1.92x1020). Since preference weights are assigned to 
each response pattern, it is impossible to design a study to elicit preference weights 
with such a vast number. The aim of this study was therefore refined, to develop a 
valid and reliable short form of the GCOS-24, amenable to future development by the 
addition of preference weights. Standardised and widely-validated PROMs such as the 
EQ-5D (Brooks, 1996) or SF-6D (Brazier et al., 2002), used in the preference-based 
evaluation of other branches of healthcare, suggest a five- or six-item measure would 
be of appropriate length. 
Additionally, the wording of GCOS-24 means it is currently unsuitable for use outside of 
CGS. The first item, for example, reads: ‘I am clear in my own mind why I am attending 
the clinical genetics service’, with responses scored on a seven-point Likert scale 
ranging from ‘Strongly Disagree’ to ‘Strongly Agree’. Genetic testing is increasingly 
being performed outside the existing models of service provision within CGS and is now 
moving into other specialities. This process is referred to as ‘mainstreaming genetics’ 
and is occurring in the context of cancer predisposition genes (Rahman, 2014), 
paediatrics (Valente et al., 2008) and neurogenetic testing (Lo et al., 2014). It is 
therefore becoming ever more important to have a valid and reliable PROM which can 
be used to evaluate genetic and genomic counselling and testing both within and 
outside of CGS. 
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Figure 2.1: The Genetic Counselling Outcome Scale 
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2.7 Conclusion 
This literature review has used existing sources to examine validated outcome 
measures used in the evaluation of CGS. The majority of existing measures were 
tailored to capture a specific outcome such as patient knowledge or satisfaction, or to 
be relevant to a specific condition such as breast cancer. Outcome-specific instruments 
only represent a limited scope of what CGS can offer patients, and condition-specific 
instruments are limited in their wider application. The extent of psychometric 
validation was largely very limited, with over half of the identified measures being 
assessed for internal consistency alone. None of the measures were preference-based - 
a requirement of NICE for any instrument used in the appraisal of efficacy and cost 
effectiveness of healthcare interventions. 
One of the aims of the literature review was to identify any candidates which may 
suitable for use as a standard measure in CGS evaluations. Three validated measures 
emerged which take into account a range of CGS patient outcomes: The Audit Tool for 
Genetics Services (Skirton et al., 2005), GCOS-24 (McAllister et al., 2011b), and the PPC 
questionnaire (Berkenstadt et al., 1999). Due to item wording The Audit Tool is 
unsuitable for pre/post intervention analysis, but the GCOS-24 and PPC are both well 
validated and have a high degree of clinical utility. GCOS-24 stands out as the stronger 
candidate since it captures empowerment, a concept which encompasses all three 
dimensions of PPC (Cognitive Control; Decisional Control; Behavioural Control), as well 
as two further dimensions (Emotional Regulation and Hope). GCOS-24 is grounded in 
extensive qualitative data and, despite being developed relatively recently, has gained 
international recognition and has been translated into multiple languages. 
If GCOS-24 is to meet NICE requirements for use in cost-effectiveness evaluations of 
CGS, it must have preference-weights attached, reflecting the value that individuals 
attach to each GCOS-24 item and response option. However, at its present length of 24 
items each with 7 response options, it is impossible to design a study to elicit 
preference weights. The aim of this study was therefore to develop a valid and reliable 
short form of the GCOS-24, five or six items in length. The short-form should be 
applicable both within and outside the context of CGS. 
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3. Methods 
The purpose of this chapter is to describe the methods used to answer the research 
objectives, including why the specific methods were chosen and how they were used. 
In some situations there were multiple potential approaches from which to choose, 
justifications as to why the chosen methods were most appropriate will be clarified. 
Research aim: to develop a valid and reliable short form of the GCOS-24, amenable to 
future development by the addition of preference weights. 
 
3.1  Study Design Overview 
There were four phases to this study. Phase I: Cognitive interviews (Ericsson & Simon, 
1980) were used to explore interpretability of GCOS-24 items and which GCOS-24 
items were most valued by the target population. Phase II: Quantitative analysis of an 
existing data set of GCOS-24 responses (n = 395), using Classical Test Theory (CTT) 
methods to identify underlying traits, and Item Response Theory (IRT) methods to 
examine item discrimination. Phase III: Item Selection. The results from Phases I & II 
were used to inform the selection of a set of five or six GCOS-24 items. The Rasch 
rating scale model (Andrich, 1978) was also used to explore functional problems with 
the seven-point Likert Scale. In Phase IV the reliability and discriminative ability of the 
new instrument was tested through a test-retest study. The overall study design is 
presented as a flow chart in Figure 3.1. 
 
 
3.2  Phase I: Qualitative Research Methods 
The overall aim of this research study was to develop a valid and reliable short-form of 
GCOS-24. One of the specific aims was to capture outcomes which are relevant to, and 
valued by, those affected by a genetic condition within the family. Items which 
represent highly valued outcomes, for example, could be considered for selection over 
those which are less valued. A second aim was to explore the meaning and wording of 
GCOS-24 items, again using the perspective, attitudes and opinions of the target 
population. Items showing as hard to interpret may benefit from rewording. 
Page 48 of 116 
 
In order to obtain this information, qualitative research methods were most 
appropriate. Qualitative methods produce rich, detailed datasets, providing effective 
ways to analyse the intricacies and variability of human emotion and beliefs (Fink, 
2016). They can be used to provide information directly from the individual’s 
perspective, making it possible to examine the relevant issues in a manner which 
quantitative analysis cannot offer (Beeson, 1997). In other words, if the purpose of the 
research is to understand the perceptions of participants, their experiences and 
interpretations, without destroying the complexity and context of the data, qualitative 
methods are most appropriate (Atieno, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Flowchart of Overall Study Design 
 
Phase I: Cognitive Interviews 
Aim: To explore which GCOS-24 items 
are perceived to be most relevant and 
most valued by those who have a 
genetic condition within their family, 
as well as item interpretability. 
Phase II: Quantitative analysis of an 
existing set of GCOS-24 responses. 
Aim: CTT methods to identify 
underlying traits within GCOS-24;  
IRT methods to examine item 
discrimination. 
Phase III: Item Selection 
Aim: To select a reduced set of 5-6 GCOS-24 
items. Likert scale optimisation. 
 
Phase IV: Test-retest Study 
Aim: To test the reliability and discriminative 
ability of the new instrument. 
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3.2.1  Cognitive Interviews 
The cognitive interview (also called ‘think-aloud’ interview) derives from the 
psychological procedures described by Ericsson and Simon (1980), and involves 
subjects being explicitly instructed to ‘think aloud’ as they answer the questions. The 
interviewer interjects infrequently where possible, and encourages interviewees to 
explain their thoughts and to expand on their answers. The great advantage of 
cognitive interviewing over other qualitative methods for the purpose of this study is 
conferred by the think-aloud premise. Olson et al. (1984) stated that using the think-
aloud technique is one of the most effective ways to assess higher-level cognitive 
processes (i.e. those which involve thought or memory), and that it was a valuable 
method for studying individual perspectives. Ericsson and Simon (1980) conclude that 
the data produced from think-aloud methods are ‘thoroughly reliable’ as a source of 
information about thought processes (p. 247). More recently, cognitive interviewing 
has emerged as one of the more prominent methods for analysing survey questions, 
with numerous academic, government and commercial research centres incorporating 
cognitive interviews into their usual procedures for questionnaire development (Beatty 
& Willis, 2007). 
If carried out with a single interviewee, cognitive interviews give each individual an 
opportunity to speak in detail and in turn allow for more data to be collected from 
each participant than focus groups (Gill et al., 2008). With respect to this study, some 
of the topics could be perceived to be sensitive or personal, and individual interviews 
allow these to be explored in private without the pressure of a group. It was also 
expected that participants may have different perspectives depending on the specific 
genetic condition in their family, and whether they are affected by, at risk for, or 
unaffected by said condition. Individual interviews give each participant a chance to 
speak freely on each question and provide their honest opinion. In short, cognitive 
interviews carried out on an individual basis were chosen as the most appropriate 
qualitative method for this study. 
Before collecting data using cognitive interviews, it is important to decide on the 
interview structure, for example the appropriate degree of prompting (Charters, 2003). 
A non-directive, semi structured method was chosen because it gives interviewees the 
opportunity to speak freely and expand on their answers whilst still ensuring that the 
researcher has some control of the interview content. ‘Non-directive’ is a term 
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denoting a technique in which the interviewer refrains from asking leading questions, 
or from directing the interviewee in their responses (Rogers, 1945). ‘Semi-structured’ is 
an interview style which allows a degree of openness and flexibility in the line of 
questioning (Longhurst, 2003). While a structured interview involves a predetermined 
set of questions from which one is not allowed to divert, a semi structured interview is 
more conversational, allowing participants to raise and explore new ideas. The 
questions and overall structure will likely be predetermined, but modifications can be 
made by the interviewer depending upon what seems most appropriate. This can be 
beneficial for data collection as it allows for a comprehensive commentary from the 
perspective of the participant, and novel and unexpected points may arise (Barriball & 
While, 1994). 
Face-to-face interviews, characterised by synchronous communication in time and 
place (Opdenakker, 2006), were chosen as preferable, but not a necessity. On the one 
hand, they allow for social cues such as body language to enrich the data. The 
interviewer and interviewee can directly react to what the other says or does, and this 
can help to create a good ambience and cultivate a good relationship between both 
parties (Opdenakker, 2006). With that said, telephone or video interviews also have 
certain benefits. They extend access to participants who would otherwise be hard to 
reach, for example mothers at home with small children, or people with disabilities 
who cannot travel. They can also be easier and cheaper to arrange and perform, with 
neither party having to travel. Whilst the ability of the interviewer to pick up on social 
cues may be reduced, telephone interviews can allow people to relax and feel able to 
disclose sensitive information (van Teijlingen, 2014). 
Regarding sample size, cognitive interview guidelines (Malterud et al., 2015) suggest 
that 10-20 participants should be sufficient to achieve data saturation (the stage at 
which the researcher can see no new themes emerging from the data). When looking 
to studies of a similar nature, a recent study by Diness et al. (2017) carried out 18 
cognitive interviews with genetic counselling patients as part of a study to translate 
and adapt GCOS-24 for use in Denmark. This lies in accordance with Guest et al. (2006), 
who reported that ‘data saturation often occurs following about 12 interviews with 
members of homogeneous groups’ (p.74). Failure to reach data saturation will likely 
have a negative impact on the quality of research as well as content validity (Bowen, 
2008; Kerr et al., 2010), so the aim of this study was to recruit a minimum of 10 
participants. 
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All interviews were audio-recorded with permission of the interviewee. Recording 
allows for an accurate and detailed method of data collection (Opdenakker, 2006). 
Coupled with this, notes were taken during interview, for example to record non-verbal 
cues and to keep track of the topics covered. 
In summary, Phase I of this study aimed to explore which GCOS-24 items are perceived 
to be most relevant and most valued by those who have a genetic condition in their 
family. Cognitive interviews present the most appropriate means of satisfying this 
objective, and the aim was to recruit 10 – 15 participants. Non-directive, semi-
structured cognitive interviews were conducted on an individual basis to provide 
information on GCOS-24 item valuation and interpretability from the perspective of the 
target population. The interview guide (Appendix D) was adapted from the guide used 
by Irwin et al. (2009), intending to last around 45 minutes. All interviews would be 
audio-recorded with permission of the interviewee, and no reward or financial 
compensation was provided. Letters of thanks were emailed to all interview 
participants (Appendix E). 
 
  3.2.2 Cognitive Interview Recruitment 
A study sample for cognitive interviews was identified using a sampling frame provided 
by Genetic Alliance UK (GAUK), a national charity comprising over 180 support groups 
for genetic conditions, aiming to provide information and support to families and 
individuals with genetic conditions, as well as influencing the services needed by these 
people. The sample was an adaptation of the GAUK ‘Rare Disease Patient Network’ (a 
collection of patients, families, health care professionals and researchers in the South-
Wales region who are interested in genetic diseases) with only patients and families 
included. 
To ensure recipient anonymity, as required by the Data Protection Act 1998, 
recruitment materials including information about the project (Appendix A) were 
dispersed by Steven Blunt, the Public Engagement and Policy Officer for GAUK. An 
email recruitment method was used in an attempt to maximise responses, and to save 
costs seeing as the project was unfunded. If an expression of interest was received, 
contact was then made by Peter Grant to arrange an interview. Informed consent was 
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confirmed immediately prior to interview through a consent form (Appendix B). For 
telephone interviews, this process was done in advance by post. 
Cognitive interview inclusion criteria were that participants: 
-  are at risk of, or affected by, a genetic condition within the family; 
-  are over 18 years old; 
-  have expressed an interest in participating in research. 
Participants were excluded if they failed to meet these criteria, and also if they were 
unable to speak or read English. Ethics approval for the recruitment of human 
participants for cognitive interviews was granted by Cardiff University School of 
Medicine, 12th May 2017 (Appendix H). 
 
 
  3.2.3  Qualitative Data Analysis 
With cognitive interviews in place in the study design, an appropriate method of data 
analysis had to be selected. Table 3.1 lists the common methodological approaches to 
qualitative analysis with brief descriptions. 
 
Table 3.1  Common methodologies for qualitative analysis. Definitions adapted from Dey (1993) 
Method Description 
Discourse Analysis The study of meanings or ideas around a topic, and how these 
are established, used, and changed. Detailed analysis of 
discourses.  
Ethnography Observational study of people in their natural environment.  
Framework Analysis Mostly deductive. A theoretical framework provides structure 
to data analysis. Patterns are identified, reported and analysed.    
Grounded Theory Entirely inductive, no preconceived idea. Theory developed 
from data. 
Interpretive 
Phenomenological 
Analysis 
How individuals make meaning of their life and experiences.  
Thematic Analysis A method for identifying, analysing and reporting patterns 
within data. A descriptive approach; can be either inductive or 
deductive. 
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Three methods from Table 3.1 could be used to analyse the cognitive interview data 
produced in this study: Grounded theory, Thematic analysis, and Framework analysis. 
Grounded theory (Glaser & Strauss, 1967) is a popular approach for exploring new 
areas, as it focuses on developing a theory purely from the data collected. The 
researcher should not be influenced by any preconceived ideas, and does not specify a 
theory beforehand. Thematic analysis (Braun & Clarke, 2006) follows a somewhat 
similar methodology, albeit less interpretative, involving the identification of themes 
within the qualitative data. Both approaches were considered, but were judged to be 
rather too inductive considering that the interview data was expected to be structured 
by GCOS-24 items and the underlying construct of empowerment; novel themes were 
not expected to arise. 
Framework analysis (Ritchie & Spencer, 1994) is a superior alternative to grounded 
theory and thematic analysis if the research has specific questions or issues, and if the 
research is primarily based on the observation and accounts of the participants 
(Srivastava & Thomson; 2009). It is a method for analysing and reporting patterns 
(themes) within qualitative data, and is becoming an increasingly popular approach in 
medical and health research (Gale et al., 2013). Its defining feature is that the 
researcher analyses data with a theoretical structure already in place to provide 
guidance. In-depth analyses of key themes can still take place, but the data provided by 
each research participant remains connected to the theoretical framework so that the 
context is not lost. It is most commonly applied for the analysis of semi-structured 
interview transcripts, allowing for easy comparisons and contrasts to be made across 
different participants (Gale et al., 2013). 
Framework analysis was selected as the most appropriate method. Empowerment was 
chosen as the framework since GCOS-24 was specifically designed to capture 
empowerment, and also to help ensure that the shortened questionnaire captures a 
range of CGS outcome domains. 
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There are five steps to Framework Analysis. 
1. First, the researcher must become familiarised with the qualitative data. 
Transcription from an audio recording will usually satisfy this step (Srivastava & 
Thomson, 2009). 
2. Secondly, a theoretical framework must be identified and applied 
(empowerment). Although data will likely reflect the a priori issues, an open 
mind must be maintained and data should not be forced to fit into 
preconceived notions. 
3. Third, data is ‘indexed’, which means identifying themes within the data. 
Ritchie & Spencer (1994) recommend that a numerical system (coding) be 
used. 
4. Charting, the forth step, involves a more detailed examination of indexed data. 
Sub-themes are labelled, and data may be placed in charts or tables headed by 
the thematic framework. 
5. The final stage is termed mapping and interpretation. This involves the holistic 
analysis of the themes and subthemes. The researcher is cognisant of the 
objectives of Framework Analysis: “to define concepts, to map the nature of 
phenomena, to create typologies, to find associations, to provide explanations, 
and to develop strategies” (Ritchie & Spencer, 1994, p186). 
 
In summary, Framework Analysis was selected as being the most appropriate method 
of qualitative analysis. The defining feature of this method is that a theoretical 
framework is used during analysis, providing structure and enabling comparisons 
between participants. In this study, empowerment was the natural choice of 
framework, since GCOS-24 was specifically developed to capture it. 
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 3.3 Phase II: Quantitative Research Methods 
  3.3.1  Parallel Analysis, Maximum-Likelihood & Rotation 
 
One of the aims of this project was to produce a measure which captures the breadth 
of the underlying construct, empowerment (Table 2.4) (McAllister et al., 2011a). Rather 
than using subjective judgement to assess this aim, Factor analysis (FA) was chosen as 
an appropriate quantitative technique. FA, first introduced by Thurstone (1931), is a 
generic term given to a class of statistical methods which aim to identify correlations 
between variables. Observed correlations are then used to group variables, with the 
concept being that correlations may be explained by latent traits. In other words, FA 
determines whether the data produced by the variables is a result of just a few 
underlying factors (Beukelman & Brunner, 2016). 
One of the main applications of FA is in the process of scale reduction (Costello & 
Osborne, 2005). Variables (questionnaire items) will ‘load’ onto the underlying factors 
differentially depending upon the observed correlations, representing the relationship 
of each variable to the underlying factor. Retaining variables with higher loading values 
will ensure that the underlying traits are being captured as best as possible. 
The alternative quantitative method of identifying underlying traits is called principal 
components analysis (PCA). PCA has long been a popular alternative to FA, due to it 
being quicker and less computationally intensive, and because it was the default option 
for early software programs (Gorsuch, 1990). Nowadays, however, with modern 
computing power, these benefits are insignificant, and many researchers argue in 
favour of FA (Bentler & Kano, 1990; Floyd & Widaman, 1995; Ford et al., 1986; 
Gorsuch, 1990; Loehlin, 1990; MacCallum & Tucker, 1991; Mulaik, 1990; Snook & 
Gorsuch, 1989; Widaman, 1990; 1993). A major flaw of PCA is that it is does not 
discriminate between shared variance (present amongst all variables) and unique 
variance (particular to each variable) (Ford et al., 1986). It therefore has a tendency to 
produce inflated values of variance for each item (Ford et al., 1986; Gorsuch, 1997; 
McArdle, 1990). 
When applied to this context, FA methods represent potentially valuable tools to assist 
in the scale reduction of GCOS-24. Indeed previous results have suggested that the 
Page 56 of 116 
 
items within GCOS-24 can be divided into factors, although FA results have not been 
consistent (McAllister et al., 2011b; Costal-Tirado et al., 2017). 
The first step was to select an FA method for identifying the optimal number of factors 
present within the data. Traditionally, default choices have been the eigenvalues-
greater-than-one rule (Kaiser, 1960), or the scree plot (Cattell, 1966). These, however, 
present problems. The eigenvalues-greater-than-one rule typically over overestimates, 
and sometimes underestimates, the number of factors (Cliff, 1988; Zwick & Velicer, 
1986), and there is a broad consensus in the current literature that this is one of the 
least accurate methods for selecting the number of factors to retain (Velicer & Jackson, 
1990). The scree test involves an eye-ball search of a plot, and as such is liable to poor 
accuracy and reliability (Crawford & Koopman, 1979; Streiner, 1998). Parallel Analysis 
(Horn, 1965) has emerged as a superior method of finding the optimal number of 
factors (Dinno, 2009; Lance et al., 2006; O’Connor et al., 2000; Velicer et al., 2000; 
Wood et al., 1996; Zwick & Velicer, 1982, 1986). Although once computationally 
intensive (Costello & Osborne, 2005), Parallel Analysis can now be carried out quickly 
using modern computers on common statistical software such as SPSS and SAS 
(O’Connor, 2000). The concept of Parallel Analysis is to identify the number of factors 
which account for more variance than can be explained by random chance. 
Although Parallel Analysis can be used to identify the number of underlying factors 
within a set of variables, it cannot be used to assign variables to the factors and 
produce factors loadings. The next decision, therefore, was to select a method for this 
purpose. Available methods include alpha factoring, generalised least squares, image 
factoring, maximum likelihood, and principal axis factoring. Articles by Fabrigar et al. 
(1999), Costello & Osborne (2005), Field (2013) and Sullivan et al., (2005) argue that if 
data are normally distributed, maximum likelihood is the best choice. For one, it is the 
only method which does not treat the sample as the entire population, instead 
assuming that participants are randomly selected. This allows for inferences to be 
made about the larger population from the sample (Felsenstein, 1981). Additionally, 
maximum likelihood shows lower variation and better reliability than other methods as 
the calculations are least affected by error (Felsenstein, 1981; Sullivan et al., 2005). 
The final decision with respect to FA methods was the rotation method. ‘Rotation’ in 
this context is a process which helps to align the observed correlations with the actual 
data points, making the factors more clearly defined and interpretable. For variables 
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which are theoretically expected to correlate (as with GCOS-24), oblique rotation is 
most appropriate. There is no widely preferred specific method of oblique rotation, all 
tend to produce similar results (Costello & Osborne, 2005; Fabrigar et al., 1999). 
 
In summary, one of the aims of this study was to maintain the ability of the reduced 
scale to capture the breadth of the GCOS-24 underlying construct, empowerment. FA 
methods were chosen as being appropriate for this purpose, specifically Parallel 
Analysis, Maximum Likelihood, and oblique rotation. These methods examine item 
correlations to identify any underlying traits within the instrument, and show which 
items correspond to those underlying traits. Items with stronger correlations (‘higher 
loadings’) better represent the underlying trait, and this information can be used to 
prioritise items for selection. 
 
  3.3.2  Item Response Theory 
A further aim of this study was to examine the discriminative ability of GCOS-24 items. 
In other words, if an item states ‘I feel positive about the future’, as with item 8 in 
GCOS-24, it should cause people who do not feel positive about the future to answer 
differently compared with those who do feel positive about the future. Items which are 
unable to discriminate between individuals of different trait levels would make poor 
candidates for selection in the reduced scale. Although the development, validation, 
and refinement of outcome measures have traditionally been guided by a set of 
quantitative approaches known as CTT (Gulliksen, 1950; Hambleton, 2000; Nguyen, 
2014; Wiberg, 2004), the issues of CTT and the advantages of IRT as outlined on page 
38 led to IRT methods emerging as the preferred choice. 
There are a number of models within the IRT family, all designed to fit a certain 
purpose. Table 3.2 lists the available methods for measurement scales with 
polytomous item response formats (more than two options, as with GCOS-24), along 
with a summary of their appropriate use. 
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Table 3.2 Polytomous Item Response Theory (IRT) Models. Adapted from Nguyen et al. (2014) 
IRT Model Model Characteristics 
Bock’s Nominal Model Used for unordered responses. Discrimination allowed to vary 
across items. 
Generalised PCM Used for ordered responses. Discrimination varies across items.  
Graded Response Model Used for ordered responses. Discrimination varies across items. 
Partial Credit Model 
(PCM) 
Equal discrimination across all items. Separate category location 
parameters estimated for each item.  
Rasch Rating Scale Model Equal discrimination across all items. A single set of categorical 
location parameters estimated for all items. 
 
Bock’s Nominal Model (Bock, 1972) operates on unordered response options which are 
in the form of nominal categories. The 7-point Likert scale of GCOS-24, ranging from 
strongly disagree to strongly agree, is an ordered rating scale response format, 
therefore Bock’s cannot be applied. The Partial Credit Model (PCM) (Masters, 1982) 
and Rasch Rating Scale Model (Andrich, 1978) assume equal discrimination across all 
items, so cannot be used to test item discrimination. The two models which allow for 
separate discrimination parameters are the Graded response model (GRM) (Samejima, 
1969) and the Generalised PCM (Muraki, 1992). Both methods are very similar and will 
generally agree very closely (Nguyen, 2014). The slight difference is that the 
Generalised PCM uses ‘local estimation’ during calculation (i.e. not all data are 
incorporated when estimating boundary parameters), which means there is no 
guarantee that the response categories will be ordered in the output (Muraki, 1992). 
The GRM, on the other hand, forces the response categories to be ordered (Samejima, 
1969), which is more appropriate for analysing the strictly ordered seven-point Likert 
scale in GCOS-24. Therefore, the GRM was selected for assessing item discrimination. 
 
 3.3.3 Application of Quantitative Methods 
Phase II used an existing dataset, comprising a set of responses to GCOS-24 (n = 395), 
collected in 2010 for the original psychometric validation (McAllister, 2011b). Specific 
details (e.g. gender, ethnicity, condition type, reason for referral) can be found in 
McAllister et al. (2011b). FA methods were conducted using IBM SPSS Statistics 23.0 
(IBM Corp., 2015); the GRM used R statistics 3.5.0 and the package ltm (Rizopoulos, 
2006); and Rasch Analysis used the Winsteps Rasch Measurement software version 
Page 59 of 116 
 
4.3.2 (Linacre, 2017). Ethics approval for the secondary use of GCOS-24 responses was 
granted by the National Research Ethics Service (NRES) Committee North West.  
 
In summary, one of the aims of Phase II was to assess the discriminative ability of 
GCOS-24 items. Items with better discriminative properties would then be prioritised 
for inclusion in the reduced scale. IRT methods provide a means of accomplishing this 
aim, as they are able to examine instruments at the item-level. The GRM was selected 
as most appropriate IRT method. 
 
 3.4 Phase III: Item Selection 
Three principles guided the approach to item selection. (i) Items with an unjustifiably 
low discrimination parameter (>1.34) were not selected; (ii) Items with factor loadings 
<0.55 were not selected; (iii) To avoid redundancy, items capturing a similar outcome 
were not selected together; FA, GRM and cognitive interview findings were used to 
establish superior items.  
The Likert scale within GCOS-24 was also examined with a view to reduction. The GRM 
naturally provides this information as part of the output, but only in the form of a 
graph. An eyeball assessment must then be made. The Rasch Rating Scale Model 
(Andrich, 1978) offers a useful supplementary method, providing numerical 
information on rating scale statistics from which purely objective conclusions can be 
drawn. 
 
 3.5 Phase IV: Validity and Reliability Testing 
Internal consistency, test-retest reliability and validity are essential properties for any 
measurement scale (Aaronson et al., 2002; Mokkink et al., 2010). Content validity, a 
subjective assessment of whether the instrument measures the appropriate content 
and represents the variety of attributes that make up the measured construct (Frost et 
al., 2007), was assured by the qualitative research underpinning GCOS-24 (McAllister et 
al., 2008; 2011a). 
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Internal consistency, described on page 21, has become the primary method of 
estimating the reliability of multi-item scales. Indeed Streiner (2003) stated that, 
“Internal consistency is necessary in scales that measure various aspects of 
personality” (p.103). 
Test-retest reliability is a different form of reliability, in which the test is administered 
at two time points. The scores from each time point are then correlated, estimating the 
extent to which scores are stable over time. Test-retest reliability is a valuable tool in 
scale development, as a scale should theoretically produce the same results if 
administered to the same group of people (McCrae et al., 2011; Schmidt et al., 2003). 
Choosing an appropriate time interval for a test-retest study is important. It should not 
be so soon that responses at the second assessment are influenced by memories of the 
first assessment, yet not so long that a change in the measured construct has occurred 
amongst respondents during the time interval. A time interval of two weeks is often 
considered appropriate for the evaluation of PRO instruments (Streiner & Norman, 
2015). The Consensus-based Standards for the selection of health measurement 
instruments (COSMIN) guidelines suggest a minimum sample size of 50 for reliability 
studies (Terwee et al., 2007). 
In order to calculate internal consistency and test-retest reliability, an online test-retest 
study was designed. An online method was used in an attempt to maximise responses, 
and to save costs seeing as the project was unfunded. Firstly, a version of the new scale 
was created using SurveyMonkey. The survey was then advertised by GAUK to their 
membership in their weekly online newsletter. The advertisement contained a brief 
description of the research study, as well as links to the survey and further project 
information (Appendix F). When a survey was completed, the respondent was emailed 
after a period of 14 – 21 days requesting them to complete the survey a second time 
(Appendix G); a final reminder email was sent if no response was received within a 
week (Appendix G). Responses were used to calculate internal consistency and test-
retest reliability. The GRM was also used to examine item discrimination within the 
new scale. Ethics approval for the recruitment of participants for the test-retest 
reliability study was granted by Cardiff University School of Medicine, 12th May 2017 
(Appendix H). 
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In summary, this project aimed to produce a reliable short-form of GCOS-24. A test-
retest study was designed with results used to calculate internal consistency, test-
retest reliability and item discrimination. The time interval for the test-retest study was 
14 – 21 days, aiming for a sample size of 50 amongst those affected by a genetic 
condition in the family. 
 
 3.6  Summary 
This chapter has described the methods used in this study to meet the study objective 
of developing a valid and reliable reduced version of GCOS-24. Justifications as to why 
the chosen methods were most appropriate were clarified, and their implementation 
was explained. The final design consisted of four phases: Phase I used cognitive 
interviews to explore the interpretability of GCOS-24 items and which GCOS-24 items 
were most valued by the target population; Phase II utilised CTT methods to examine 
underlying traits within GCOS-24, and IRT methods to examine item discrimination; in 
Phase III the results from Phases I & II were used to inform the selection of set of 5-6 
GCOS-24 items; and in Phase IV the reliability and discriminative ability of the new 
instrument was tested through a test-retest study. Chapter 4 will present the results of 
the study. 
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4. Results 
 
This chapter will present the results obtained over the course of the project. For clarity 
the structure will follow the four-phase structure as described in the methods chapter. 
Phase I will present the results from the cognitive interviews, including participant 
demographics and framework analysis. In Phase II the results from the quantitative 
analyses will be described, and then in Phase III how both the qualitative and 
quantitative data were used to inform item selection for the short-form GCOS-24. 
Finally, in Phase IV, results from the test-retest reliability study will be presented, 
including an assessment of item discrimination using the Graded Response Model. 
 
4.1 Phase I: Cognitive Interviews 
Recruitment was carried out across June and July 2017. Thirty-five individuals were 
invited to participate in the study, ten of whom replied expressing their interest in 
participating (response rate 28.6%). Of these, all ten were successfully interviewed.    
Think-aloud cognitive interviews were conducted on an individual basis across June, 
July and August 2017. Five face-to-face interviews took place at the Institute of Medical 
Genetics at Cardiff University, three face-to-face interviews took place at the 
participant’s place of work or residence, one was conducted by telephone and one was 
conducted by Skype. Participant characteristics are summarised in Table 4.1. For 
anonymity, participants are identified with the letter P followed by a number. Proof of 
diagnosis of genetic condition was not requested, but all participants believed that 
their condition was genetic. 
Qualitative data was analysed using Ritchie & Spencer’s framework analysis method. 
This is described in detail in section 3.2.3, but in short interviews were transcribed and 
empowerment was applied as the theoretical framework. Data was then indexed to 
identify themes within the data, and findings were ‘charted’ which involved a more 
detailed process of labelling and sorting, bearing in mind the empowerment 
framework.. The qualitative framework analysis findings are presented below. Item 
numbering will be referred to in GCOS-24 (Figure 2.1), and a summary of the most 
highly-valued items is provided in Table 4.2 on page 65. 
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Table 4.1: Cognitive interview participant characteristics 
 
 
4.1.1 Cognitive Control 
Part of feeling empowered in relation to a genetic condition in the family is having a 
belief that you have sufficient knowledge and understanding about the condition 
(Cognitive Control) (McAllister et al., 2008). This could be knowledge about how the 
condition is inherited, what causes it, what the signs and symptoms are, and what the 
implications are for the rest of the family, both at present and in the future. All ten 
participants spoke of their desire to learn more about their condition, both at the time 
of diagnosis and as an ongoing pursuit, and of the benefits that this knowledge could 
have on their lives. On an item level, six GCOS-24 items had originally been designed to 
capture cognitive control: items 1, 3, 12, 14, 18, and 23. Of these, items 18 (‘I don’t 
know who else in my family might be at risk for this condition’) and 12 (‘I don’t know if 
this condition could affect my other relatives (brothers, sisters, aunts, uncles, cousins)’) 
appeared to be valued most highly by participants. Knowing how the condition might 
affect one’s relatives was judged to be very useful information. This participant spoke 
of item 18: 
“That’s a really good question because if you, if this was day one, so you ask 
someone before their first session, they’re probably going to answer that quite 
Participant Sex Condition Affected, At risk, 
Unaffected 
Has a 
child? 
Received 
Genetic 
Counselling? 
P1 Male Nystagmus Affected No No 
P2 Male Ataxia Affected No Yes 
P3 Female Tubular Sclerosis Unaffected Yes Yes 
P4 Male Glaucoma Affected No Yes 
P5 Female Thalassemia 
Intermedia 
Affected Yes Yes 
P6 Female Episodic Ataxia Unaffected Yes No 
P7 Female Ehlers Danlos 
Syndrome 
Affected Yes No 
P8 Female Dystonia & Ataxia Affected Yes No 
P9 Female Huntington’s Disease At risk Yes Yes 
P10 Male Leber’s Hereditary 
Optic Neuropathy 
Affected No No 
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high. If you ask them after 5 sessions, then actually the answer could be 
completely the opposite, so I think that’s a valuable question to ask, because 
you can show the progress they’ve made and what they’ve learnt from the 
session. I think that’s a really good question. And before I had the genetic 
counselling I would have answered I don’t know, and now I can answer I do 
know, because I had the service and got the information that I needed.” (P4) 
Another participant, when considering item 12, stated: 
“I think it is an important piece of knowledge to have. If I didn’t know that 
information I would be worried, and I could see how people would get worried 
about that type of thing” (P5). 
Items 12 and 18 emerged as strong candidates for retention (Table 4.2). 
 
 
4.1.2 Decisional Control 
Decisional Control within the empowerment framework is not restricted only to 
decisions made about healthcare. It can include any major or minor decision which is 
influenced by having a genetic condition within the family (McAllister et al., 2008). This 
might involve decisions on marriage, whether or when to have children, or on 
seemingly unrelated decisions such as buying a car or whether to take on a mortgage. 
Outcomes relating to Decisional Control were discussed by some participants in this 
study, for example this interviewee who had a daughter with episodic ataxia: 
... “To me, reading that [item 24], it’s just what I do anyway, I make decisions 
for her. If I feel she can’t do something in the normal way, then I find other 
routes which enable her to do everything anybody else is doing. To me that is 
making a decision. So you’re always decision making, always, you can never 
stop decision making for the child.” (P6) 
 
The corresponding GCOS-24 items (10, 13 and 24), however, were rarely chosen by 
participants as being of high value. More specifically, items 13 (‘In relation to the 
condition in my family, nothing I decide will change the future for my children / any 
children I might have’) and 24 (‘I can make decisions about the condition that may 
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change my child(ren)’s future / the future of any child(ren) I may have’) suffered 
because they were not seen as relevant by the 40% of participants who did not have 
children. Item 10 (‘I don’t know what could be gained from each of the options 
available to me’) was of unclear meaning to many: 
... [Interviewer: “Are any items difficult to understand?”] “I suppose number 
10: I don’t know what could be gained from each of the options available to 
me. That’s a little bit, what options are we talking about?” (P1) 
... [Interviewer: “What does item 10 mean to you?”] “Umm. Well the first thing 
that comes to mind after reading that question is, I don’t know what options it 
means. Umm. As far as I’m concerned I had genetic counselling, and now I’ve 
just got to see my consultant, take my medication... and that’s it. I don’t know 
any options that are available to me at all. So, it doesn’t mean a lot to me.” 
(P3) 
No items within Decisional Control emerged as strong candidates for selection. 
   
 
4.1.3 Behavioural Control 
Behavioural Control is perhaps the most diverse dimension of empowerment, 
representing the perception of an individual that they are able to take action to 
improve their situation. This includes making effective use of the health and social care 
systems which are available, managing the condition day to day, or communicating 
about genetic risks with relatives (McAllister et al., 2008). All participants spoke at 
length about the importance of outcomes corresponding to Behavioural Control. 
Topics included their experiences with the NHS, the vital importance of both medical 
and non-medical services following diagnosis with a genetic condition, and how 
important it is to be able to communicate with others about the condition, whether 
that be with family, work colleagues, or with a school on behalf of their child. This 
participant, for example, spoke of her experience with local support groups: 
... “The [support] groups are a massive help. I forced my sister to join. I do think 
that having a network of people going through the same thing, it doesn’t 
matter what your situation is, whether it’s, you know, cancer, depression, or 
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anything that’s happened, if you’ve got a group of people going through the 
same thing you are, it’s ultimately just support and it will always help.” (P5) 
 
On an item level, almost all items designed to capture Behavioural Control were valued 
by participants. Especially popular were items 2 (‘I can explain what the condition 
means to people in my family who may need to know’) and 16 (‘I can explain what the 
condition means to people outside my family who may need to know’), with all ten 
expressing the benefits of being able to talk about the condition. This participant 
contextualised this outcome within social situations: 
... “Most people I think are naturally inquisitive. If they can see or know that an 
individual has a condition, disability, call it what you want, and if you’re able to 
talk comfortably about it, and other people around you can talk comfortably 
about it, and answer what may sometimes seem ignorant or silly questions, 
and you’re happy to take those questions, then that’s in the best interest of 
everybody. Whether it is family, friends, or work colleagues, whatever, it 
makes life easier for everybody.” (P1) 
These participants spoke of item 16: 
... “For example my son is starting comp in September and I’ve had to put a 
thing on his medical notes saying that he’s got thalassemia intermedia. His 
school then rang me, asked what that entailed and would he suffer in any 
aspects, so I told them about it.” (P5) 
... “I feel very passionate about doing that [being able to explain the condition] 
and sort of being out there and making sure everyone knows about the 
condition.” (P2) 
  
A comparable problem was observed with respect to items 7 (‘I can control how this 
condition affects my family’) and 22 (‘I am powerless to do anything about this 
condition in my family’), due to the contrasting interpretations over the meanings of 
‘control’ and ‘powerless’: 
... “I’ve got control over how people react to it, over how much people need to 
know, or how they act around my child. Obviously I can’t control how ill he’ll 
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get. [...] I think that’s the bit of control I’ve got, he will be very confident. He’s 
going to be brought up very confident, and very, you know, not embarrassed 
about anything.” (P3) 
... “See I don’t like, I would take out control and I would put manage. I can’t, 
we have no control. We can only do things to lessen the impact, or try to lessen 
the impact. [...] So I don’t think you can control, ever control it. I think you can 
try and manage the condition. But control, no.” (P7) 
... “You’ve got no control over it [the condition]. Get over yourself.” (P2) 
... “I don’t know about control. [...] It’s more empowerment and advocacy of 
ownership, those are the things. Those are the terms I would be more likely to 
use over control. I don’t use control, or very rarely.” (P1) 
... “I mean, you can’t change genetics can you. I don’t know ... are you 
powerless? I think we’re all dealt with a hand of cards and how you deal with 
the hand you’ve got is the bit that determines whether you’re powerless. You 
can’t suddenly change your genetics, you know if I wanted to have a different 
colour skin I can’t change that genetically can I. Uh powerless, such a strange 
term. I guess in pure genetic terms I can’t change my own genetics so in that 
instance yeah, I guess I would be powerless.” (P4) 
... “I am powerless about this condition in my family. That can mean numerous 
things though can’t it. Because like I can’t control genetics, but I think I can 
affect change in my life now I know about it.” (P6) 
 
Aside from item 7 and 22, all items in Behavioural Control emerged as candidates for 
selection (Table 4.2). 
 
  4.1.4 Emotional Regulation 
Emotional Regulation in the empowerment framework refers to the ability to manage 
the emotional aspects of a genetic condition, both individually and within the family 
(McAllister et al., 2011a). The diagnosis of a genetic condition can raise significant 
emotional challenges, and it is important that these emotions are addressed by any 
provider of genetic counselling or testing services. In this study, outcomes such as guilt, 
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anxiety, blame, helplessness and sadness were brought up by participants as well as 
feeling “lost” (P6), “damaged”(P4), or “broken” (P4). 
Items 4, 11, and 21 were designed to capture Emotional Regulation. Of these, item 4 
(‘When I think about the condition in my family I get upset’) emerged as the strongest 
candidate. This interviewee spoke of the item: 
... “That [item 4] is very, very important. Because it’s just like you’ve walked 
into a brick wall. All of a sudden you’re going forward and somebody will put 
this brick wall in front of you, and to me that brick wall is ataxia, and oh you 
just don’t know how to get through that brick wall. So you need people there 
to say well actually it’s not such a brick wall there is a doorway just over by 
here, let’s get around it and go through. So yeah you do need people in place 
for that especially when they’re first diagnosed.” (P6) 
Item 21 (‘I feel guilty because I (might have) passed this condition on to my children’) 
was irrelevant to those without children. Item 11 (‘Having this condition in my family 
makes me feel anxious’) was highly valued by some, but overall the findings suggest 
that anxiety levels do not necessarily reduce in the long term, and instead fluctuate 
depending on the situation. This would not be a desirable item to have in an 
instrument which measures patient benefits from CGS. 
... “Having the condition in my family makes me feel anxious... I don’t think 
that will ever fully go away. I’m anxious for him [the son] when he starts a 
family. What if he gets someone pregnant and he hasn’t stopped the 
hydroxycarbamide? It does happen. I’m anxious for my future grandchildren. 
[...] Knowing more about it [the condition] has made me less anxious in one 
respect, but more anxious in other respects. I am very anxious because, even 
though I know a lot, I don’t feel I know everything.” (P5) 
... [Interviewer: “Does the anxiety improve over time?”] “The anxiety? ... no. 
Because the minute she has another episode you sort of take a deep breath 
and you hold it until she comes out of this episode.” (P6) 
Item 4 emerged as the strongest candidate for retention (Table 4.2). 
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       4.1.5 Hope 
Positivity, or a positive mind-set, was the chief manifestation of hope in this study. 
Item 19 (‘I am hopeful that my children can look forward to a rewarding family life’) is 
only applicable to those with children, and even within that demographic appeared to 
be of questionable relevance: 
... “I don’t see why you’re asking that as part of genetic counselling [laughs]. I 
just think that everybody, who would say no to that? [Continues laughing] ‘I’m 
going to have kids and I hope that they have a c**p life!’ So I don’t, if you’re 
trying to evaluate the results of these questions, I can’t see how that would 
help the service at all; because everybody always wants the best for their 
children. I can’t imagine anybody not answering positively to that.” (P4) 
Item 6 (‘I can see that good things have come from having this condition in my family’) 
was criticised for being irrelevant: 
... “I can see that good things have come from having this condition? No, no I 
don’t see that. Because we’re a close family anyway and whether this 
condition was there or not there we would still be the same close family, so 
that to me, that’s an irrelevant question. I can see good things that have come? 
No.” (P6) 
... “Ah... well we’ve got Cal [the son], ummm, I guess it makes you feel thankful 
in different ways doesn’t it, makes you appreciate little things. But... no I 
wouldn’t think that was very relevant to this sort of thing, personally.” (P3) 
Item 8 (‘I feel positive about the future’) and item 20 (‘I am able to make plans for the 
future’) emerged as the strongest candidates. Both received some criticism for being 
vague, but nevertheless were highly valued. 
... “I mean number 8 is good, I feel positive about the future. Possibly a little bit 
vague. It doesn’t actually specify; somebody might think that their horse is 
going to come in tomorrow at some race and they’re going to win a whole lot 
of money. They might be positive because of that.” (P1) 
... “I like number 8, it’s a nice all encompassing statement. But what if 
somebody has some other issue or some other hope in their mind and they 
think, ‘oh yeah I’m positive’, it doesn’t have anything to do with this.” (P1) 
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... “I think it’s a good question to have in there [item 8], but it’s just a case of, I 
feel positive about the future, it’s like what aspect of the future? I feel positive 
about the future of my health, or the future of my mental health, or just feeling 
positive about the future in general. I think it’s just a bit too open ended.” (P5) 
... [Item 20] “That’s why we went really. You know, we were thinking about 
having a family. We needed the information before we put the plan in place. So 
yeah, that’s quite a valid question.” (P4) 
... [Item 20] “How far in the future do they mean? Do they mean a few weeks, 
or a few years into the future? Our lives are constant planning, everything has 
to be risk assessed and planned in advance, there is very little that we can do 
spontaneously. Umm. I don’t know. It’s a difficult one because how far in 
advance are they asking you to look? Am I looking to plan 5 years, or am I 
looking to when my kids are adults? It’s difficult, I can’t really answer it.” (P7) 
Items 8 and 20 emerged as the strongest candidates for retention. 
 
Table 4.2: Cognitive interview item valuation. Items have been grouped according to which sub-
dimension of McAllister’s five-dimensional empowerment framework each was designed to 
capture. 
Dimension of Empowerment Corresponding GCOS-24 
Items 
Highly Valued Items* 
Cognitive Control 1, 3, 12, 14, 18, 23 12 or 18 
Decisional Control 10, 13, 24 None 
Behavioural Control 2, 5, 7, 9, 15, 16, 17, 22 2 or 16; 5 or 15; 17; 9 
Emotional Regulation 4, 11, 21 4 
Hope 6, 8, 19, 20 8 or 20 
*Highly valued items with a similar meaning are separated by ‘or’. 
 
In summary, Table 4.2 presents the items which were most valued by cognitive 
interview participants. Empowerment was sufficient to integrate all themes which 
arose, however no item capturing Decisional Control was highly valued. Considering 
the diversity of outcomes within Behavioural Control, and the high value given to them 
by participants, it was observed that multiple items may merit inclusion if they capture 
different aspects of the dimension. 
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One noticeable trend throughout the interview process was the confusion experienced 
by participants when answering items beginning with ‘I don’t know’. Of the ten 
participants, seven selected a response option contrary to what they meant when 
asked about such an item. One individual recognised this when asked about item 18 (‘I 
don’t know who else in my family might be at risk for this condition’): 
... “Erm... so I would disagree to that [item 18]. Because it’s like a negative isn’t 
it. Umm if I’ve read it correct. So it says I don’t know, but actually I’m saying I 
do know, so I would have to disagree with that statement. So that might be 
slightly confusing to someone. You may get a couple of false positives, if 
someone misunderstands the question. It is common for these, I’ve done it 
myself when I’ve had to write these kind of evaluations, as soon as you put in 
the word ‘I do not’ or ‘I don’t’, you know those kind of things, you sometimes 
get people who misunderstood the question. So I would I would say strongly 
disagree or disagree. Because after the service I did know [who else in my 
family might be at risk for this condition].” (P4) 
 
The result of this finding was an agreement within the research team that any items 
containing ‘I don’t know’ would be reworded to ‘I know’ if selected for inclusion in the 
reduced scale. 
 
 
4.2 Phase II: Quantitative Analysis 
  4.2.1 Parallel Analysis & Maximum Likelihood 
Table 4.3 shows the results of Parallel Analysis. The first five raw data eigenvalues all 
exceed the eigenvalues produced for random data at the 95th, the statistically 
significant, percentile. The sixth raw data eigenvalue however (1.138) does not exceed 
that produced for random data. This shows that the variance in the raw data is greater 
than can be explained by random variation up until the 5th, but not the 6th eigenvalue, 
suggesting an optimal five-factor structure. 
Maximum Likelihood was used to determine how the five-factor structure 
recommended by Parallel Analysis fits to GCOS-24. The pattern matrix is presented in 
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Table 4.4, results ordered and loadings <.3 excluded. For clarity, Likert scale responses 
to negatively worded questions were reversed and are labelled with the suffix ‘P’. In 
order to capture empowerment in the new scale, it may be beneficial to select items 
with high loading values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.2 The Graded Response Model 
Tables 4.5 - 4.9 present the numeric GRM results for GCOS-24 items, grouped by 
empowerment dimension. The extremity parameters (Extrmt n) show the latent trait 
score at which people have a 50/50 chance of selecting certain responses. The 
discrimination parameter (Dscrmn) represents the slope of the curve at the point 
where the probability of endorsing an item is 50% (also referred to as item difficulty), 
and describes how well an item can differentiate between individuals of varying ability. 
Root Raw Data Percentile 
1 4.706 1.550 
2 3.090 1.452 
3 1.970 1.384 
4 1.451 1.332 
5 1.292 1.284 
6 1.138 1.241 
7 .964 1.200 
8 .929 1.163 
9 .865 1.128 
10 .781 1.091 
11 .717 1.061 
12 .693 1.025 
13 .633 .992 
14 .605 .961 
15 .561 .933 
16 .525 .901 
17 .493 .871 
18 .478 .842 
19 .442 .812 
20 .411 .784 
21 .371 .753 
22 .324 .721 
23 .289 .687 
24 .271 .648 
 Factor 
 1 2 3 4 5 
GCOS 8 .753     
GCOS 9 .691     
GCOS 4P .617     
GCOS 11P .606     
GCOS 20 .567     
GCOS 19 .400     
GCOS 21P .385   .375  
GCOS 2  .799    
GCOS 3  .764    
GCOS 16  .364    
GCOS 14   .830   
GCOS 23   .778   
GCOS 1   .517   
GCOS 17P    .641  
GCOS 18P    .628  
GCOS 22P    .603  
GCOS 12P    .515  
GCOS 10P    .509  
GCOS 13P    .494  
GCOS 5P    .411  
GCOS 7     .659 
GCOS 6     .490 
GCOS 15     .372 
GCOS 24     .357 
Table 4.3 (left): Parallel analysis. The Root column lists the number of factors, with a maximum of 24, one for each 
variable. The Raw Data column lists the eigenvalues produced by the raw data set. The Percentile column lists the 
eigenvalues produced by the parallel analysis method for random data at the 95
th
 percentile (statistically significant).  
Table 4.4 (right): Maximum Likelihood. Factor loadings have been ordered and loadings < .3 have been excluded. 
The letter P indicates that the Likert scale responses have been reversed for these items. 
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Table 4.5 – GRM results for GCOS-24 items within Cognitive Control 
 Extrmt 1 Extrmt 2 Extrmt 3 Extrmt 4 Extrmt 5 Extrmt 6 Dscrmn 
GCOS1 -2.87 -2.32 -1.91 -1.54 -1.16 0.15 2.48 
GCOS3 -4.03 -2.79 -2.19 -1.00 -0.32 1.53 0.94 
GCOS12 -45.64 -11.55 -0.72 14.79 20.70 43.39 0.04 
GCOS14 -2.46 -2.28 -2.21 -1.69 -1.00 0.29 3.51 
GCOS18 4904.26 17.62 -1307.90 -3508.13 -4319.39 -9424.74 0.00 
GCOS23 -3.54 -2.63 -2.39 -1.66 -1.03 0.50 2.04 
 
Table 4.6 – GRM results for GCOS-24 items within Behavioural Control 
 Extrmt 1 Extrmt 2 Extrmt 3 Extrmt 4 Extrmt 5 Extrmt 6 Dscrmn 
GCOS2 -3.09 -2.29 -1.89 -1.20 -0.59 1.01 1.39 
GCOS5 -4.03 -2.54 -1.75 -0.55 0.07 1.94 0.73 
GCOS7 -2.16 -0.33 0.18 2.67 3.74 6.84 0.59 
GCOS9 -3.95 -2.30 -1.55 -0.25 0.56 2.76 1.05 
GCOS15 -2.33 -0.99 -0.65 0.58 0.95 2.31 1.30 
GCOS16 -2.65 -1.85 -1.44 -0.29 -.18 1.41 1.79 
GCOS17 -3.07 -0.81 0.06 1.80 2.36 4.33 0.84 
GCOS22 -2.47 -0.28 0.66 3.15 4.26 6.98 0.47 
 
Table 4.7 – GRM results for GCS-24 items within Decisional Control 
 Extrmt 1 Extrmt 2 Extrmt 3 Extrmt 4 Extrmt 5 Extrmt 6 Dscrmn 
GCOS10 5.01 2.93 1.96 -2.83 -3.33 -5.54 0.63 
GCOS13 4.67 1.43 0.78 -2.49 -3.69 -7.35 0.46 
GCOS24 3.75 2.43 1.92 -0.49 -1.09 -3.20 0.87 
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Table 4.8 - GRM results for GCS-24 items within Emotional Regulation 
 Extrmt 1 Extrmt 2 Extrmt 3 Extrmt 4 Extrmt 5 Extrmt 6 Dscrmn 
GCOS4 -0.98 -0.24 0.28 0.94 1.09 1.94 3.65 
GCOS11 -1.23 -0.22 0.47 1.18 1.39 2.02 2.47 
GCOS21 -2.27 -1.10 -0.38 1.57 1.73 2.67 0.91 
 
Table 4.9 – GRM results for GCOS-24 items within Hope 
 Extrmt 1 Extrmt 2 Extrmt 3 Extrmt 4 Extrmt 5 Extrmt 6 Dscrmn 
GCOS6 -2.17 2.49 3.30 10.16 12.20 17.60 0.20 
GCOS8 -2.22 -1.48 -0.97 -0.29 0.37 1.67 1.69 
GCOS19 -4.97 -4.47 -3.76 -1.51 -1.08 0.52 0.95 
GCOS20 -1.96 -1.52 -1.30 -0.75 -0.33 0.65 4.32 
 
 
Using the guidelines provided by Baker (2001) for interpreting item discrimination 
parameter values, verbal labels can be applied. Table 4.10 states the thresholds for 
each verbal label, and table 4.11 lists all GCOS-24 items in rank order by discrimination 
parameter and the associated verbal label. 
 
Table 4.10 – Verbal labels for item discrimination parameters. 
Verbal Label None Very Low Low Moderate High Very High Perfect 
Range 0 .01 - .34 .35 - .64 .65 - 1.34 1.35 - 1.69 >1.70 Infinity 
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Table 4.11 – GCOS-24 items ranked by discrimination parameter and verbal label. 
Item Dscrmn Label Item Dscrmn Label 
20 4.32 Very High 3 0.94 Moderate 
4 3.65 Very High 21 0.91 Moderate 
14 3.51 Very High 24 0.87 Moderate 
1 2.48 Very High 17 0.84 Moderate 
11 2.47 Very High 5 0.73 Moderate 
23 2.04 Very High 10 0.63 Low 
16 1.79 Very High 7 0.59 Low 
8 1.69 High 22 0.47 Low 
2 1.39 High 13 0.46 Low 
15 1.30 Moderate 6 0.20 Very Low 
9 1.05 Moderate 12 0.04 Very Low 
19 0.95 Moderate 18 0.00 Very Low 
 
The GRM item characteristic curves (Appendix I) provide an illustration of the numeric 
results. Figure 4.1 presents the GRM output for item 15 as an example of an item with 
moderate to high discriminative ability (1.30). Clear peaks can be seen ordered from 
‘Strongly Disagree’ at low levels of the latent trait to ‘Strongly Agree’ at high levels of 
the latent trait. Each curve, however, is not especially distinct, largely overlapping with 
its neighbour. Figure 4.2 presents the GRM output for item 22, an item of low 
discrimination (0.47). 
 
Figure 4.1: Example GRM item characteristic curve. Item 15 – Dscrmn = 1.30. 
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Figure 4.2: Example GRM item characteristic curve. Item 22 – Dscrmn = 0.47 
 
The GRM item information curves (Appendix I) show how well and precisely each item 
measures the latent trait across various levels of said trait. Certain items may provide 
information at low levels of the trait, while others may provide more information at 
higher levels. Comparing item information curves allows a comparison to be made 
between items on how well the latent trait is represented by the item. An example 
item information curve is provided in Figure 4.3. The plot includes items designed to 
capture ‘Emotional Regulation’, and shows that item 4 would be the best candidate. 
The application of the item information curves to item selection is described in Phase 
III. 
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Figure 4.3: Example GRM item information curve (Emotional Regulation) 
 
 
4.3  Phase III: Item Selection 
One aim of this study was to develop a measure which could be used outside the 
context of CGS. Items 1, 14 and 23 were therefore not considered for selection because 
they specifically refer to ‘clinical genetics services’. The three principles of item 
selection will now be addressed. 
 
(i) Items with an unjustifiably low discrimination parameter (>1.34) were not selected: 
Item discrimination parameters and associated curves were assessed, and those items 
with a ‘High’ or ‘Very High’ discrimination parameter were retained. For the other 
items, a flexible approach was used for data interpretation, since it was recognised that 
a number of factors may contribute to an item’s quantitative properties. For example, 
because the cognitive interview findings indicated that a significant proportion of 
respondents experience confusion when answering items beginning with ‘I don’t 
know’, such items were not immediately rejected for displaying inferior discrimination. 
Additionally, items asking specifically about children were expected to show a 
prominent peak for Option 4 (‘Neither Agree nor Disagree / Not Applicable’). Following 
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consideration, item 3 (Dscrmn = 0.94); item 5 (0.73); item 6 (0.20); item 7 (0.59); item 
10 (0.63); item 13 (0.46); item 19 (0.95); item 21 (0.91); item 22 (0.47) and item 24 
(0.87) showed an unjustifiable inability to discriminate and were therefore removed 
from further consideration. 
 
(ii) Items with factor loadings <0.55 were not selected. 
Comrey and Lee (1992) suggest the following threshold values for factors analysis: 0.32 
(Poor), 0.55 (Good), 0.63 (Very good), 0.71 (Excellent). Of the 11 items remaining in 
consideration, item 15 and item 16 presented with factor loadings <.55, in factors 5 
and 2 respectively (Table 4.4). These items are poor representatives of empowerment 
and were therefore removed from further consideration. At this stage of item 
selection, nine items remained in consideration (Table 4.12). 
 
Table 4.12: Items in consideration following the second principle of item selection. 
Dimension of 
Empowerment 
GCOS-24 Item 
Cognitive C (12) I don’t know if this condition could affect my other relatives (brothers, sisters, 
aunts, uncles, cousins). 
Cognitive C (18) I don’t know who else in my family might be affected by this condition. 
Behavioural C (2) I can explain what the condition means to people in my family who may need to 
know. 
Behavioural C (9) I am able to cope with having this condition in my family. 
Behavioural C (17) I don’t know what I can do to change how this condition affects me/my children. 
Emotional R (4) When I think about the condition in my family, I get upset. 
Emotional R (11) Having this condition in my family makes me feel anxious. 
Hope (8) I feel positive about the future. 
Hope (20) I am able to make plans for the future. 
 
(iii) To avoid redundancy, items capturing a similar outcome were not selected 
together; FA, GRM and cognitive interview findings were used to establish superior 
items. 
Cognitive Control: Items 12 (‘I don’t know if this condition could affect my other 
relatives (brothers, sisters, aunts, uncles, cousins)’) and 18 (‘I don’t know who else in 
my family might be at risk for this condition’). Both items were highly valued by 
cognitive interview participants (Table 4.2), and quantitative results were very similar.  
The descriptive information included in the parenthesis appeared to improve 
interpretability for item 12 so item 18 was removed from further consideration. 
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Behavioural Control: All remaining items were considered sufficiently distinct. 
Emotional Regulation: Item 4 (‘When I think about the condition in my family, I get 
upset’) was selected over item 11 (‘Having this condition in my family makes me feel 
anxious’) because it was valued more highly by interviewees (Table 4.2), because it has 
a superior item discrimination parameter (3.65 to 2.47) (Table 4.11), and because the 
qualitative data suggested that anxiety levels may not reduce over time in people 
affected by a genetic condition, but instead fluctuate depending on the situation. This 
is not a desirable property in a scale designed to measure outcomes. 
Hope: Item 8 (‘I feel positive about the future’) was selected over item 20 (‘I am able to 
make plans for the future’) for two reasons. Firstly, although both display high / very 
high discrimination, item 20 has significant ceiling effects (Figure 4.4). Secondly, item 8 
has a factor loading of .753, compared to .567 of item 20 (Table 4.4). 
 
 
Figure 4.4: Item 20 item characteristic curve showing ceiling effects. 
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The reduced scale was constructed using the six items remaining with no justifiable 
reason for exclusion (2, 4, 8, 9, 12, 17) (Table 4.13). 
 
Table 4.13: The final six items. 
GCOS-
24 item 
Retained Items Empowerment 
Dimension 
2 I can explain what the condition means to people in my family who 
may need to know. 
Behavioural 
Control 
4 When I think about the condition in my family, I get upset. Emotional 
Regulation 
8 I feel positive about the future. Hope 
9 I am able to cope with having this condition in my family. Behavioural 
Control 
12 I don’t know if this condition could affect my other relatives 
(children, brothers, sisters, aunts, uncles, cousins).  
Cognitive 
Control 
17 I don’t know what I can do to change how this condition affects 
me/my children. 
Behavioural 
Control 
 
 
.  4.3.1 Likert Scale Optimisation 
Figure 4.5 presents the results of the Rasch Rating Scale analysis. At low levels of 
empowerment, option 1 (Strongly Disagree) has the highest probability of response. 
Likewise option 7 (Strongly Agree), has the highest probability of response at positive 
levels of empowerment. Option 4 (Neither Agree nor Disagree) is the most likely to be 
chosen at the zero point. Options 3 and 5 (Slightly Disagree and Slightly Agree) have 
low probabilities of being chosen and do not show distinct peaks, suggesting that they 
could be removed without compromising scale quality; GRM results support this 
suggestion. It was decided that a five-point scale would be adopted, with a view to 
possible further shortening following results from the test-retest study. 
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Figure 4.5: Rasch Rating Scale results. Each curve corresponds to a GCOS-24 response option, 
(1) Strongly Disagree to (7) Strongly Agree moving left to right. 
 
Figure 4.6 shows the proposed scale, termed GCOS-6. Based on cognitive interview 
results, items were reworded to change ‘I don’t know’ to ‘I know’ to eliminate the 
possibility for confusion over double-negatives. 
 
 
 
 
 
1 I can explain what the condition means to people in my family who may 
need to know. 
1 2 3 4 5 
2 I know the chance that this condition could affect my other relatives 
(children, brothers, sisters, aunts, uncles, cousins). 
1 2 3 4 5 
3 When I think about the condition in my family, I get upset. 1 2 3 4 5 
4 I am able to cope with having this condition in my family. 1 2 3 4 5 
5 I know what I can do to change how this condition affects me/my 
children. 
1 2 3 4 5 
6 I feel positive about the future. 1 2 3 4 5 
Figure 4.6: GCOS-6 
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4.4 Phase IV: Validity and Reliability Testing 
Face validity and content validity of GCOS-6 was assessed within the research team: 
Prof Angus Clarke (Clinical Professor) and Dr Marion McAllister (Senior Lecturer and 
Programme Director for the Genetic and Genomic Counselling MSc) at Cardiff 
University; Prof Katherine Payne (Professor of Health Economics) and Dr Maria 
Pampaka (Senior lecturer and psychometrician) at the University of Manchester. GCOS-
6 content validity was also supported by the existing GCOS-24 content validity 
(McAllister et al., 2011b). 
In the test-retest reliability study, 170 GAUK members affected by a genetic condition 
in their family responded to the advertisement and completed the online measure at 
T0. Of these, 96 (56.5%) completed the measure again at T1. Reliability as measured by 
the intraclass correlation coefficient was 0.788. Internal consistency (Cronbach’s α) was 
α = .570. GRM item characteristic curves are presented in Figures 4.7 – 4.12. Item 1 (‘I 
can explain what the condition means to people in my family who may need to know’) 
(Fig 4.7) and item 2 (‘I know the chance that this condition could affect my other 
relatives (children, brothers, sisters, aunts, uncles, cousins)’) (Fig 4.8) show significant 
ceiling effects. Indeed item 2 suggests that respondents select ‘Strongly Agree’ across 
all empowerment levels. Considering that respondents were all active GAUK members 
with an interest in research, these findings are not surprising. Item 3 (‘When I think 
about the condition in my family, I get upset’) displays clear peaks but some positive 
skew. Items 4, 5 & 6 (Fig 4.10 – 4.12) display clear peaks and no skew. 
 
 
In summary, this chapter presents the results obtained over the course of the project. 
Qualitative and quantitative data were used to create a six-item, five-level version of 
GCOS-24: GCOS-6 (Figure 4.6). Three principles were used to guide item selection: (I) (i) 
Items with an unjustifiably low discrimination parameter (>1.34) were not selected; (ii) 
Items with factor loadings <0.55 were not selected; (iii) To avoid redundancy, items 
capturing a similar outcome were not selected together; FA, GRM and cognitive 
interview findings were used to establish superior items. GCOS-6 displays good test-
retest reliability (0.788) and moderate internal consistency (α = .570). Item 
discrimination was generally good, with some understandable ceiling effects given the 
study sample of active GAUK members. 
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Figure 4.7 (top left) – 4.12 (bottom right): GCOS-6 GRM results. T0 = Time point zero. Q = 
Question e.g. Q1 (I can explain what the condition means to people in my family who may need 
to know). 
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5. Discussion 
This chapter will discuss the reported results in the context of published research 
regarding patient outcomes in genetic counselling and testing services (CGS).  The 
potential impact of the study within CGS will be considered, as well as the range of 
implications for future research and clinical practice. The discussion will include an 
assessment of the strengths and limitations of the study, and will conclude by 
commenting on the whether the aims and objectives of the study have been achieved. 
 
5.1 Results in Context of Published Research 
This research has developed a new short-form (6-item) version of the Genetic 
Counselling Outcome Scale (GCOS-24), potentially suitable for use in research, clinical 
audit, and clinical evaluations of CGS. The new scale, GCOS-6, shows good test retest 
reliability (0.788), whilst providing a less burdensome measurement scale for 
respondents and producing a significantly reduced number of response permutations 
(1.56x104) compared to GCOS-24 (1.92x1020). Additionally, with genetic testing 
increasingly being performed in contexts outside the traditional models of service 
provision (Lo et al., 2014, Rahman, 2014; Valente et al., 2008), GCOS-24 items 
specifically referring to clinical genetics services were omitted from GCOS-6, making 
the new instrument appropriate for use both within and outside the context of clinical 
genetics. Ultimately this study represents a step towards the development of a 
preference-based patient-reported outcome measure (PROM) which could be used for 
the economic evaluation of CGS. 
This study reports the first use of Item Response Theory (IRT) analysis on GCOS-24, 
contributing to the growing body of evidence that IRT methods confer many benefits 
over the traditional approaches of classical test theory (CTT), and supporting the call 
for wider use of IRT methods in PROM development (Embretson, 1996; Hambleton et 
al., 1991; Hambleton & Jones, 1993; Nguyen, 2014; Reeve, 2002). Nevertheless, IRT 
findings should be interpreted with caution when analysing subjective topics.  Item 
performance may be influenced by a variety of factors, and may be representing a 
minor issue in wording rather than the importance or quality of the underlying 
outcome. GCOS-24 items asking about children, for example, showed a prominent peak 
for the ‘Not Applicable’ response option in their item characteristic curves regardless of 
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the outcome domain being captured, reflecting the reality that not all CGS users have 
children; items beginning with ‘I don’t know’ generally performed very poorly, 
reflecting the qualitative results which suggest that many people misinterpret the 
double-negative. Rather than taking IRT results at face value, reasonable judgement 
should be applied. 
The same rule is true for classical methods, and the factor analysis carried out in Phase 
II provides a good example. Factor analysis is a tried and tested method, using 
correlations between response patterns to determine which items capture similar 
underlying traits. Correlations, however, may be due to unexpected causes.  In this 
study, all five GCOS-24 items beginning with ‘I don’t know’ were grouped into the same 
factor. Three dimensions of empowerment are represented, including themes of 
decision-making, knowledge of the condition, and powerlessness. Taking into account 
the qualitative findings which indicate participant confusion over items beginning with 
‘I don’t know’ it is likely that the correlations in this factor were due to this rather than 
any underlying trait. 
Even internal consistency, a key requirement for any questionnaire intended for use as 
a PROM (Mokkink et al., 2010; Terwee et al., 2012), is open to interpretation. Since the 
calculation is based upon item correlations, random error averages out as one adds 
more items, so in practice Cronbach’s α is affected by the length of the scale (Streiner, 
2003). Scales over 20 items will generally have acceptable values of α (>.7), whereas 
scales with fewer items will have fewer correlations from which to draw upon and in 
turn may present with lower internal consistencies (Streiner, 2003). It is therefore not 
entirely unexpected that the internal consistency of GCOS-6 (α=.570) is significantly 
lower than that of GCOS-24 (α=.870). Whilst it is understandable that internal 
consistency is highly recommended for a new measure, holding all scales to the same 
threshold is problematic. In short, quantitative methods offer powerful tools for PROM 
development, but results must be interpreted with reason. 
Evaluations of CGS have traditionally examined such outcome variables as information 
recall, reproductive intentions and decisions made, and patient satisfaction. Measures 
of process such as waiting times and numbers of patients seen have also been used, as 
well as the performance characteristics of genetics tests (e.g. sensitivity, specificity and 
predictive values) (Clarke et al., 1996; Payne et al., 2008; Wang et al., 2004). It is widely 
argued by clinical genetics professionals that traditional approaches to CGS evaluation 
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are neither relevant nor appropriate, nor are they highly valued as outcomes by 
patients and their families (Clarke et al., 1996; McAllister et al., 2008; Payne et al., 
2008). GCOS-6 captures outcomes which are relevant to and valued by the population 
of individuals who use CGS, demonstrated through the extensive qualitative research 
collected in GCOS-24 development and the cognitive interviews in this study. 
Moreover, existing outcome measures used in evaluations of CGS have generally been 
designed to capture a specific outcome or a restricted number of outcomes, often with 
respect to a single genetic condition (Payne et al., 2008). Indeed over half of the 
measures identified in the literature review were used in the evaluation of CGS for 
inherited cancer, commonly breast cancer, and many were bespoke measures 
developed for use in a specific study (Section 2.4.2: p33). GCOS-6 has been designed to 
capture a range of potential patient outcomes relevant to any potential CGS user with 
any condition, and to provide information to clinicians on patient benefits which may 
be useful for service development and audit of process. With that said, the omission of 
an item capturing the Decisional Control outcome domain is concerning. Outcomes 
relating to Decisional Control, such as informed decision making, have been proven to 
be valued by CGS users (Clarke et al., 1996; Legare et al., 2016; McAllister et al., 2008; 
McAllister et al., 2011a; Metcalfe, 2018; Miller et al., 2005), and were discussed by 
participants at interview. Clinical use of GCOS-6 may be held back by this omission, and 
a potential area of future research could be the development of a valued and relevant 
item which can capture Decisional Control for all potential CGS patients. 
Finally, this study supports the use of both quantitative and qualitative methods when 
approaching the task of scale development. In its ideal form, a mixed methods 
approach can represent a happy marriage between theory and empirical confirmation, 
providing unique strengths and offsetting the weaknesses of either approach alone. 
For instance, qualitative research is strong when used to understand the context or 
setting in which people behave, including their perspectives, attitudes and opinions. 
Quantitative methods can offer little information in this respect. On the other hand, a 
weakness of qualitative research is the potential for researcher-bias to affect data 
collection and interpretation; quantitative methods do not have these weaknesses. 
Taken together, incorporating a mixed methods approach into the study design can 
help to provide a complete and comprehensive understanding of the research 
problem. 
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5.2 Implications for Practice 
Patient engagement is increasingly acknowledged as a key component in the process of 
service improvement in healthcare, with recent evidence affirming that patients who 
are engaged in their care perceive improved outcomes (Remmers et al., 2009). 
Historically, with the exception of collecting feedback on satisfaction or experience 
with care, patients have been an untapped resource when evaluating the quality of 
healthcare and of long-term support services (National Quality Forum, 2013). The 
introduction of routine use of PROMs to the NHS in 2009 was a landmark development, 
reflecting the growing recognition throughout the world that the patient’s perspective 
is highly relevant to efforts to improve the quality and effectiveness of healthcare. To 
this end, valid and reliable instruments such as GCOS-6 provide essential tools. 
The routine use of PROMs by the NHS has generated considerable interest from other 
countries, including Canada, Germany, New Zealand and Sweden (Devlin & Appleby, 
2010). With that said, although PROMs offer enormous potential, there are at present 
only four procedures that are covered by the National PROMs programme, accounting 
for only around 3.3% of all elective activity in the UK (Devlin & Appleby, 2010). 
Extending the coverage of PROMs, especially into areas of NHS activity which have 
traditionally lacked universal measures of quality and effectiveness, is a challenge 
which can only be met through the establishment of valid outcome measures. 
Designing and implementing PROMs in certain branches of healthcare, such as CGS and 
mental health services, may prove more challenging since care pathways and patient 
outcomes may be significantly more complex in comparison to those branches which 
involve discrete treatment events, the success of which can be measured in objective 
terms e.g. surgical interventions. 
As well as widening the scope of PROMs coverage, developing valid and reliable 
PROMs such as GCOS-6 could offer other potential benefits, such as the 
encouragement of a more coordinated system for comparisons of healthcare quality, 
and the provision of additional sources of information for NICE evaluations of 
healthcare interventions. Indeed a significant problem faced by NICE is the dearth of 
appropriate or robust evidence from healthcare practice. PROMs are also appreciated 
by healthcare professionals as a tool to complement their own clinical judgement and 
encourage their professional development (Boyce & Browne, 2014; Costal-Tirado, 
2017). The introduction of routine PROMs collection has potentially important 
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implications for enlarging the base of real-world evidence on cost-effectiveness that 
NICE can draw upon to inform its guidance to the NHS. 
The National Quality Forum (NQF) is a neutral standards-setting organisation in the US 
which endorses outcome measures used to assess the quality of healthcare based on 
well-vetted, widely accepted criteria. Along with the baseline requirements of validity 
and reliability, these criteria include being ‘Person Centred’ and ‘Meaningful’. The 
concepts measured by the PROM should be relevant and important from the 
perspective of patients and their families, ideally capturing health-related quality of life 
(HRQoL) impacts. GCOS-6 satisfies these criteria, and indeed GCOS-24 is currently in 
the process of being endorsed by the NQF. 
In an economic context, the NHS faces the sizeable challenge of bringing about £22 
billion worth of productivity improvements by the year 2020/21 (ref) and as such there 
is currently a considerable focus on efficiency and cost-effectiveness within the 
healthcare system. As financial and workload pressures increase, it is important that 
both human and monetary resources are targeted where they are most effective, and 
that the provision of services is modified according to need. In this time of budget 
constraints, and rising costs, in healthcare, the rapid advances in CGS are a source of 
both hope and concern. On the one hand, these services have the potential to benefit 
the population in many ways, for example by enabling the early detection of hereditary 
predispositions to specific diseases, and by offering support and guidance to those 
affected by a genetic condition within the family. From a financial perspective 
however, genetic interventions can be extremely costly (Ref?). Any increases in funding 
would likely come at the expense of another service, and so such actions must be 
thoroughly justified in the eyes of decision makers looking to maximise benefits per 
unit cost. 
In order to help determine the allocation of resources amongst competing healthcare 
interventions, the NHS uses economic evaluations. One of the most common methods 
is cost-effectiveness analysis, which compares interventions in terms of their cost per 
quality adjusted life years (QALYs) gained. A QALY value is calculated through the use 
of two variables: (i) the change in a patient’s health status, quality of life (QoL), or 
health related quality of life (HRQoL); (ii) the change in a patient’s length of life (in 
terms of ‘years’). With this in mind, if a service is going to be amenable for economic 
evaluation, it must have a clear set of patient outcomes laid out in terms of their 
health, QoL or HRQoL, as well as a means of measuring the outcomes. Additionally, 
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NICE have called for outcome measures used in service evaluation to be preference-
based, to reflect the value that individuals attach to each item and response option. 
GCOS-6 serves as a promising first step in the development of a preference-based 
PROM which can be accepted as the standard for use in economic evaluations of CGS. 
This research is especially timely since the rate at which economic evaluations of CGS 
are being carried out and published has increased greatly over recent years (Carlson et 
al., 2005; Djalalov et al., 2011; Andrea et al., 2015). Rapid advances in genetics 
technology, coupled with the current financial pressures, have led to a demand for 
economic evaluations to help identify which interventions confer greater health gains 
per unit cost. This was exemplified by Andrea et al. (2015), who carried out a 
systematic review of primary economic evaluations of predictive genetic and 
pharmacogenetic testing programs from inception until 2012. Of the 128 articles 
identified, almost 40% were published in the three years from 2010-2012. 
 
 
 5.3 Implications for Future Research 
The development of GCOS-6 opens up a number of avenues for future research. One 
option would be to construct a relevant and valued item to capture the Decisional 
Control dimension. Decisional Control is a vital dimension of patient empowerment 
(McAllister et al., 2011a), and one of the central tenets of genetic counselling is that 
the counsellor should adopt a ‘non-directive’ approach, trying to help the client arrive 
at the best decisions from their own perspective, rather than guiding them towards 
any particular decision (Elwyn et al., 2000). The process of genetic counselling may 
involve the facilitation of a decision making process in relation to prenatal diagnosis or 
the termination of a pregnancy; it may relate to a decision about predictive genetic 
testing. Some decisions may be particularly complex, involving a balance between the 
risk of a procedure and the benefit of obtaining diagnostic information.  
Recent studies have found that, although patients are better informed today than in 
the past, there is dissatisfaction and frustration due to inadequate personal input into 
their decisions about treatment (Jun et al., 2016; Nicholls et al., 2013; Pae et al., 2014). 
In the US, empowering patients and families to actively engage in decision-making has 
been emphasised in the Patient Protection and Affordable Care Act (2010), and by 
national agencies such as the Agency for Healthcare Research and Quality (2015). It is 
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therefore likely that the construction and implementation of an item representing 
Decisional Control to GCOS-6 will be of benefit to the scale. 
Sensitivity to change (responsiveness) is one of three quality domains, along with 
reliability and validity, recommended for all new measures by COSMIN guidelines. It 
relates to the ability of an instrument to detect change over time. The minimally 
important difference (MID) is another important concept in measurement scale 
development, providing a measure of the smallest change in the outcome that patients 
perceive as important. Neither the MID nor the responsiveness of GCOS-6 were tested 
in this study. Assessment of these measurement properties will help to ascertain 
whether GCOS-6 is a robust instrument and to identify possible areas for improvement. 
COSMIN guidelines also recommend the use of IRT methods in the development and 
evaluation of measurement properties (Terwee et al., 2012). Whilst the graded 
response model (GRM) was used in this study to assess item discrimination, there are a 
number of other methods which fall within the scope of IRT, each offering unique 
characteristics. One particular avenue for future research could be to use the Rasch 
model (Rasch, 1966) to explore the extent to which GCOS-24 and GCOS-6 measure the 
same construct, thereby indicating how well GCOS-6 captures empowerment. An 
appropriate sample size for IRT analysis is around 100 individuals (Terwee et al., 2012). 
The Rasch model is a goodness-of-fit test, applying constant item discriminating 
powers and calculating a result based on item scores and overall estimates of item 
difficulties. Going further, were an item to be implemented which represents 
Decisional Control, the Rasch model could indicate the degree to which this new 
instrument agrees with GCOS-24 in comparison to GCOS-6. 
IRT methods could also be used to examine the rating scale statistics of the five-point 
Likert scale within GCOS-6, with a view to further reduction. Two potential benefits 
may arise from this. Firstly, reduction of the Likert scale would result in an even lower 
number of potential health state values, streamlining the process of attaching 
preference weights (Brazier et al., 2002). At its current length, of six items each with 
five levels, GCOS-6 has 1.56x104 possible response permutations, greatly reduced from 
GCOS-24 (1.92x1020) and similar to the widely-used preference-based EQ-5D 
instrument (3.13x103). Secondly, rating scale statistics may help to optimise the GCOS-
6 Likert scale by identifying redundant response options. 
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5.4 Strengths and Limitations 
One of the great strengths of GCOS-6 is that it was developed from GCOS-24: an 
internationally recognised PROM with demonstrated validity, reliability and 
responsiveness which specifically measures patient outcomes valued by CGS patients 
and service providers (McAllister et al., 2011b). Indeed GCOS-24 content validity has 
previously been demonstrated for CGS (McAllister et al., 2011b), and clinical utility has 
been demonstrated both in the UK and internationally (Diness et al., 2017; Inglis et al., 
2014; McAllister & Dearing, 2015; Munoz-Cabello et al., 2017). The substantial 
qualitative research underpinning GCOS-24, coupled with the further qualitative 
research in the current study, supports the potential implementation of GCOS-6 for 
service evaluation in CGS and in future research. 
A further strength of this study was the large sample size achieved for the test-retest 
reliability analysis (n=96), a figure meeting the COSMIN quality criteria for assessment 
of the methodological quality of studies on measurement properties of health 
instruments (Terwee et al., 2012). A weakness, however, was sample homogeneity. 
During the interview stage all ten participants were white-British and resident in South-
Wales. Cognitive interview results are therefore limited to the perspective of families 
who live in a specific region and speak English. Additionally, only one of the ten 
interviewees was classified as ‘at-risk’ for a genetic condition. Seven were affected and 
two were unaffected themselves but had an affected child. At-risk individuals are a key 
target demographic for CGS, and higher representation would have been beneficial. 
For the test-retest reliability study, sample homogeneity could be a possible 
explanation for the ceiling effects observed with certain items. Individuals who join 
GAUK, take an active interest in research projects, and volunteer themselves for such 
projects, are likely to have a good understanding of their condition. Such individuals 
may also have higher levels of empowerment than the majority of patients referred to 
CGS, a suggestion supported by McAllister et al. (2011b) who found that active patient 
support group members were significantly more empowered than those who did not 
attend support groups. In order to develop an outcome measure, and indeed a service, 
which caters to all needs it will be necessary to collect data from a wide range of CGS 
users, particularly those which could be classified as ‘hard to reach’. 
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5.5 Conclusion 
In conclusion, GCOS-24 has been shortened to a six-item measure with a five-point 
Likert scale (GCOS-6). GCOS-6 offers a genetics-specific measure which is applicable 
both within and outside the context of clinical genetics, capturing a range of potential 
patient outcomes for individuals affected by any genetic condition. The new 
instrument will be less burdensome to patients than GCOS-24 and psychometric testing 
indicates that GCOS-6 has good test-retest reliability. Further testing, however, for 
example to examine interpretability and responsiveness, will be necessary before 
GCOS-6 can be recommended unreservedly for routine evaluations of genetic 
counselling and testing services. Obtaining data from hard to reach demographics will 
be of particular benefit in constructing an instrument relevant to the entire population 
of service users. Future developments to GCOS-6 could involve the addition of an item 
representing Decisional control, and the attachment of preference weights reflecting 
the value placed on items by CGS users. Overall, this study represents the first step in 
developing a preference-based measure which could be used in the evaluation of 
genetic counselling and associated testing services. 
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6. Reflective Discussion 
In this chapter I shall reflect more informally on the reality of the research process 
compared to what was planned. I will outline the practical pitfalls which I have 
experienced and hypothetically what I would do differently. Lessons learnt during the 
process will be scattered throughout, before concluding with some advice I might pass 
on to any future students undertaking an MPhil. 
 
 6.1 Starting Out 
Prior to starting this project I had no experience with clinical genetics research, and 
little idea of what the genetic counselling process involved. Undergraduate studies had 
included modules on cell biology, molecular biology, and genetics, but clinical genetics 
seemed to occupy an individual niche, separate from other areas of Biology. Looking 
back now, I was far too slow to build up a foundation of knowledge in this new field. 
Rather than taking the time early on to read extensively and gain a thorough 
understanding of the basic principles, I rushed ahead and began learning how to 
perform the quantitative methods. 
My lack of understanding was evidenced through some sub-par work in the initial 
stages of the project for which I can only apologise to my supervisor for subjecting her 
to. One essay in particular comes to mind, where I neither took the time nor had the 
mental awareness to realise that the empowerment construct I was meant to be 
studying was distinct from empowerment in other areas of science. Over time I caught 
up, but I am sure that I could have saved myself a great deal of time and a great deal of 
misplaced effort had I taken the necessary steps to properly inform myself in the early 
weeks. 
It was also during these initial stages that I was advised to scrutinise the proposed 
study design; to examine every planned method and provide a justification for its use 
over other available methods. This was excellent advice, which shall stay with me 
moving forward. At the time, however, as a lowly student with no background in 
clinical genetics, the idea of seriously questioning the study design did not occur to me. 
Instead, I took the study design as gospel and worked backwards, supplying 
justifications based on a known end-point. In short, I did not take ownership of the 
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project fast enough. I followed directions and did as instructed, but I failed to step up 
and apply independent thought in the initial stages. 
More excellent advice came my way early on when I was told to construct a Gantt 
chart showing the project timeline, and to circulate it around the research team. 
Having never used a Gantt chart before I was unsure how much value one would be, 
but again this proved to be a lesson which I will take with me and apply to future work. 
Of particular benefit was the ability to visualise the timescale for each stage of the 
project and to adjust deadlines accordingly.  
Linked on to this, one major difference I found with this MPhil, as opposed to 
undergrad, was the necessity to take other parties into account when aiming for a 
deadline. An undergrad semester is only 11 weeks in total, and for most assignments 
the student is entirely responsible for their own work. If an essay is to be written, for 
example, no-one else can influence the time which one’s essay is handed in. At 
postgrad, however, other people must be considered. The person you need to contact 
may be on holiday; the interview participant may ask to delay until next week. 
Depending on the circumstances it may be polite to circulate a piece of work around 
the research team prior to submission. If this is the case, they may ask for a couple of 
weeks to provide feedback, and then their feedback will have to be applied. Suddenly a 
submission deadline which is four weeks in the future becomes a top priority. I began 
to build in buffer periods to the study design in case of unforeseen delays which are so 
common in research. The importance of prior planning was a valuable lesson from this 
project. 
 
 6.2 Recruitment 
The online recruitment method proved to be an excellent choice. Response rates were 
pleasing and the process was much faster than if materials had been sent out by post. 
It was also much cheaper, which is not an unimportant consideration for an unfunded 
project. With that said I perhaps should have explored other recruitment sources to try 
and overcome sample homogeneity. A wider catchment area, for example, could have 
been used. Local events, clinics or focus groups could have been contacted. Again this 
goes back to my sluggishness in taking ownership of the project. The application for 
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ethics approval was submitted in March, and by the time I realised that more 
recruitment options could be beneficial, the window of opportunity had long closed. 
The only serious complication to occur during the project came in the recruitment 
phase. A representative from GAUK had very kindly agreed to help recruit participants 
for cognitive interviews by contacting GAUK members on my behalf. Months later, 
however, following a disappointing campaign in which only ten participants were 
recruited, it was discovered that the mailing list was not exclusively for individuals 
affected by genetic conditions. Once academics, GAUK staff and the like had been 
removed, only 35 of the initial 130 email addresses remained. With time marching on it 
was not possible to explore other avenues or apply for further ethical approval. 
Although a specific example, I have taken away a wider warning to leave no stone 
unturned during the study design and to make sure that back-up options are in place in 
case the initial plan unexpectedly fails. 
The recruitment process, coupled with consistently excellent advice from my 
supervisor, helped to develop my confidence in email communication. Indeed at the 
start of the project I was often reluctant to send emails for fear of troubling the 
recipient. Likewise If I didn’t receive a response to an email, I would be very hesitant to 
chase it up. Over the course of this year I feel that I have become more confident in 
drafting correspondence, and in finding the balance between being polite, grateful, and 
concise. 
 
 6.3 Methodology 
The most enjoyable moments of the project came when carrying out the methods. The 
cognitive interviews were immensely interesting as they provided a real-world 
perspective of living with a genetic condition, and working with statistics is a particular 
pleasure of mine. Nevertheless, I believe in hindsight that some elements of the 
methodology could have been changed. 
For one, I believe that Factor Analysis (FA) could have been discarded from the study 
design. FA was selected to provide an objective approach to identifying underlying 
traits within GCOS-24, a decision which in theory was sound. FA is a popular method in 
scale development, and had previously been used in the construction of GCOS-24 
(McAllister et al., 2011b) and the Audit Tool for clinical genetics (Skirton et al., 2005). 
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The problem with using FA in this context was that GCOS-24 had been specifically 
designed to capture empowerment, a five dimensional-construct developed through 
extensive qualitative research. Whilst I recognise the benefit of FA methods for 
researchers wishing to avoid subjective or arbitrary criteria for factor retention, I 
believe that the qualitative evidence supporting the dimensions of empowerment was 
sufficient to supersede FA for the purposes of this study. Additionally, FA is not a 
foolproof method of determining underlying traits, since the correlations used to 
produce factor loadings may arise as a result of unexpected influences. This was 
evidenced in this study by the fact that all items beginning with ‘I don’t know’ fell into 
the same factor, regardless of the apparent outcome domain. All in all, I believe in 
hindsight that FA was superfluous given the existing presence of empowerment. 
It is unclear whether a more liberal approach to altering GCOS-24 would have resulted 
in a superior final scale. Operating under the reasoning that any changes made to the 
meaning of an item would require separate validation, an initial decision was made 
that only minor alterations to improve item interpretability would be permitted. A 
purist, however, might argue that any change whatsoever could affect the meaning 
and therefore would require separate validation, and in turn that the decision to 
replace ‘I don’t know’ with ‘I know’ was mistaken. The possibilities of a more liberal 
approach are interesting to consider. Similar items could have been combined to 
encompass a broader range of outcome e.g. Item 2 (‘I can explain what the condition 
means to people in my family who may need to know’) and item 16 (‘I can explain what 
the condition means to people outside my family who may need to know’) could 
perhaps have been combined to read ‘I can explain what the condition means to other 
people who may need to know’). Alternatively, item 24 (‘I can make decisions about 
the condition that may change my child(ren)’s future / the future of any child(ren) I 
may have’) could have been reworded to ‘I can make decisions about the condition 
that may change my future’ and included as a representative of Decisional Control. 
With that said, providing solid justifications for such changes could prove challenging. 
With the rules on GCOS-24 alterations as they were, certain GCOS-24 items could have 
been immediately discounted from analysis. Items specifically referring to the ‘clinical 
genetics service’, for example, were never going to be selected for the short-form as 
the aim was to create a measure appropriate for use both within and outside the 
context of clinical genetics. Similarly it could have been recognised that items 
pertaining to children would not be relevant to a significant proportion of CGS users. 
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Removing unsuitable items ab initio would have reduced participant burden during 
interview and would have simplified the quantitative analysis. 
 
 6.4 Advice to Peers 
In the interest of brevity I have narrowed my advice down to two points. 
1. Pursue other interests outside of the project.  
It is very easy for a prolonged PhD or MPhil project to take over one’s life. There are 
always deadlines looming, there are always pages to be written, and there is always 
work to be done. An uncompromising work ethic may pay off in the short term, and 
may have proven fruitful during the short semesters of undergrad study, but in my 
opinion is not conducive to a happy and productive life when faced with a project 
lasting up to four years. 
It may sound trivial, but the recent push by universities to consider mental health is no 
accident. If left unchecked, the cloud of a PhD project can hang overhead at all hours of 
the day. It can surround you and consume you and can be hard to escape from, 
especially if the project is oriented on independent research. Working alone on a 
project, staring at a laptop all day can make for a lonely time. This is particularly 
relevant in a period where there is so much entertainment available through the 
screen of a phone or computer. 
So to any future student I would pass on the advice to join a society, join a sport, and 
make a point of attending on a regular basis. It could be badminton or ballroom 
dancing, wine tasting or poetry reading, find something which interests you, something 
which maybe doesn’t involve a computer screen, and get involved. University offers a 
wealth of opportunity in this respect and I certainly believe that extra-curricular 
activities are an important dimension of university life. Furthermore, whether you’re 
new to the area or not, get outside of the Cathays bubble once in a while, leave work 
behind and explore Wales. It will be refreshing and invigorating. 
With regards to the work, many people have found great success in treating PhD 
research like a nine-til-five job, confining the project to working hours and keeping 
evenings and weekends free. Personally, sport has always played a large part of my life 
and served as my escape; I also had a part-time job in a cocktail bar. For me, regular 
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extra-curricular commitments helped to provide a structure to my time and to cultivate 
the much mentioned ‘work-life balance’ which despite its clichéd usage represents an 
important philosophy. 
 
2. Plan ahead with specific, time-bounded goals. 
Self-discipline was crucial to my research project. Aside from a weekly meeting with my 
supervisor, which later became a monthly meeting, my time was my own. I could get 
out of bed at any time, I could work as much or as little as desired, or not work at all. 
Whilst this had certain benefits, for example being able to plan my time as I wished and 
fit work around my other commitments, it was often difficult to find the motivation to 
work. Therefore I would advise any student carrying out independent research to 
generate a mentality of self-discipline rather than self-motivation. Motivation is 
fleeting, unpredictable, and too often absent altogether. Motivation can be distracted 
by YouTube or delayed by a hangover. Discipline, I feel, is a much better alternative. 
That said, discipline is not always easy, so I would advise someone with no structure or 
pressure to their time to generate a structure and a pressure. Write a to-do list and set 
discrete objectives which can be achieved in the short term. Plan deadlines ahead of 
time and note the relevant dates. For example, if your supervisor gives you a month to 
write a Literature Review chapter, take the time before getting started to break down 
the deadline into smaller chunks e.g. “From 2pm to 5pm every day I will read at least 
10 papers, making notes in MS word and logging the details in a spreadsheet. After one 
week I will design a preliminary structure to the review and plan the to-do list for the 
next week.” Vague, amorphous goals will not prove fruitful. 
As well as helping to maintain my work ethic, artificial deadlines provided a structure 
to the project timeline. I would encourage any research student to expend some effort 
early on in planning realistic and detailed deadlines, to take the deadlines seriously, 
and to update the deadlines if circumstances change. As mentioned earlier, Gantt 
charts and buffer periods have proved useful in my experience to visualise the 
timescales and to allow some flexibility. I would advise a new student to pay particular 
attention to the time required for ethics applications and to get those applications in as 
early as possible. On a smaller scale, I would advise them to not develop a habit of 
unnecessarily delaying the minor tasks e.g. replying to emails. If indulged, this can 
easily lead to more significant delays in the project as a whole. 
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Finally, if I may, I’d like to end with a quote from Alexandre Dumas’ Count of Monte 
Cristo. I first read the book not long before starting this project, and the following lines 
have stayed with me as I have tried with varying levels of success to get to grips with 
the field of genetic counselling. The protagonist, Dantes, who has wrongfully been 
thrown into solitary confinement, has managed to make contact with an old man in the 
neighbouring cell. The old man possesses considerable knowledge and wisdom, 
proficient in mathematics, physics, history and languages, and has just offered to teach 
Dante everything he knows over the next two years: 
“Two years!” exclaimed Dantes; “do you really believe I can acquire all these 
things in so short a time?” 
“Not their application, certainly, but their principles you may; to learn is not to 
know; there are the learners and the learned. Memory makes the one, 
philosophy the other.” 
 
I thank you for your consideration of this thesis. 
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I would like to be a participant 
Thank you! If you are happy to help with the study, please complete the consent form 
below. 
If you would like to learn more about the study, or if you have any questions, please 
contact: Peter Grant, Email: grantp2@cardiff.ac.uk Telephone: 029 2074 4055 
Title of Project: Developing a Questionnaire for the Evaluation of Clinical Genetics Services 
 
Name of Researcher: Peter Grant           Please initial box 
 
1. I confirm that I have read and understand the information sheet for the above study and           
have had the opportunity to ask questions. 
2. I understand that taking part is voluntary and that I do not have to answer any questions                I 
do not wish to. I understand that I can leave the study at any time without explanation. 
  
3. I consent to my details and data being used by the research group, as laid out in the 
    information sheet. I understand that data will not be shared beyond the research group.  
             
4. I agree to the interview being audio-recorded 
 
5.  I agree to take part in the above study. 
    
 
________________________ ________________ ____________________ 
Name of Participant Date Signature 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ ________________ ____________________ 
Researcher Date Signature  
 
Clinical Genetics Research Study 
Participant Consent Form 
Division of Cancer & Genetics 
School of Medicine 
Cardiff University 
Heath Park Campus 
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Why are we doing this study? 
We want to develop a short questionnaire which can be used to evaluate genetic 
counselling and testing services. More specifically, we would like to hear feedback from 
patients, family members, and others so that we can build the best questionnaire possible. 
We want to help genetic counselling and testing services focus on what patients really want 
from their healthcare. The study will begin on May 1st 2017 and finish on January 1st 2018. It 
is an ‘unfunded’ study, forming part of the research of Cardiff University MPhil student 
Peter Grant. 
Why have I been chosen? 
You have been chosen because you are, or have a connection to, an individual with a 
genetic condition. We believe that you have the relevant knowledge and experience to help 
us in our research. 
What will I have to do?  
There will be one meeting lasting 30-50 minutes. You can come to us or we can come and 
meet you. Alternatively interviews can be carried out by phone or Skype. You will be asked to 
read through and answer five or six questions, each to do with clinical genetics, and 
discuss your thoughts about each one. We will then ask you some further questions about 
the questionnaire, and we encourage you to speak freely and honestly. With your consent, 
the meeting will be audio-recorded. Unfortunately, as this is an unfunded student research 
project, we cannot offer reimbursement for any travel costs incurred as part of the research study. 
How much time will the study take? 
The study will take 30-50 minutes in a single meeting. 
Do I have to take part? 
Taking part is entirely voluntary, and there will be no consequences if you decide not to take 
part.  
Can I withdraw? 
You are free to leave the study at any time, with no consequences. 
 
Clinical Genetics Research Study 
Participant Information Sheet 
Title:  Developing a Questionnaire for the Evaluation of Clinical Genetics Services 
Invitation 
You are being invited to participate in a research study which aims to help improve the quality of 
care provided by clinical genetics services. Before you make a decision we would like you to 
understand why the research is being done and what your participation will involve. Please take the 
time to read the following information carefully and discuss with others if you wish. If you have any 
questions, or if you would like more information, please feel free to ask. 
 
  
Genetic Alliance UK 
Wales Gene Park 
Cardiff 
CF14 4XN 
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Who is carrying out the study? 
The study is being carried out by MPhil student Mr Peter Grant, and is supervised by Dr 
Marion McAllister (Senior Lecturer in Genetic Counselling, Cardiff University); Prof Angus 
Clarke (Clinical Professor in Medical Genetics, Cardiff University); Prof Katherine Payne 
(Professor in Health Economics, University of Manchester). 
Will the study benefit or disadvantage me? 
We do not expect that the study will harm or disadvantage you in any way. Also we do 
not guarantee that there will be any benefits to you from taking part in the study. You will 
not have to answer any questions which make you uncomfortable, and you can choose to 
leave the study at any time without giving a reason. We cannot guarantee compensation in 
the event of something going wrong, and unfortunately, as this is an unfunded student research 
project, we cannot offer reimbursement for any travel costs incurred as part of the research study. 
Can I tell other people about the study? 
Yes you are welcome to tell other people about the study.  
What will happen to the results of the study? 
The results will be used by the researchers to help develop the questionnaire, and for no 
other reason. Data will not be shared with anyone outside of the research study team. Your 
answers and comments will be analysed and compared to see if other people have said 
similar things. What you say may be used to re-word some of the questions to help make 
them more clear. All aspects of the study, including results, will be strictly confidential and 
only the researchers will have access to information on participants. If the results form part 
of a report, it will not be possible to identify individual participants in any way. 
Will my personal information be confidential? 
All data will be strictly confidential and only the researchers will have access to your 
personal information. Cardiff University has strict rules and standards on confidentiality, and 
these rules will be followed. The results from completed questionnaires will be made 
anonymous and all personal information removed. Likewise, your name will not be used and 
you will not be identifiable on any interview transcripts or interview excerpts in any 
publications arising from the research. 
All personal information will be kept in a locked cabinet in the office of the Principal 
Investigator Dr Marion McAllister, located in the Institute of Medical Genetics, Cardiff 
University Heath Park Campus. 
I have concerns about the project 
For any concerns about how the research is being / was conducted, please contact the 
public engagement and policy officer for Genetic Alliance UK - Steven Blunt. Email: 
blunts@cardiff.ac.uk 
 
Contact Us 
If you would like more information or have questions about this study, please contact: 
Steven Blunt, Email: blunts@cardiff.ac.uk. Telephone: T: +44 (0)2920 748 154 
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Interview Guide 
Interviews will follow a semi-structured format. This guide provides an outline of discussion topics 
and will act as a reference to prompt conversation where necessary. 
A non-directive approach shall be taken. The participant will be encouraged to ‘think out loud’, 
verbalising his/her thoughts as s/he answers survey questions. The interviewer will be primarily 
passive, providing prompts and encouragement where necessary and asking open-ended questions.  
Introduction 
- Welcome 
- Brief explanation of research project 
- Give participant GCOS-24, explain and ensure understanding 
- Description of the interview format 
- Hand participant PIS, review selected points 
- Participant questions 
- Signing of consent form  
o Permission for audio recording included 
Recorded Interview 
 Introductory questions (~5mins) e.g.: 
o Ask the participant to talk about themselves 
o Connection to a genetic disorder or clinical genetics. 
o Encourage to expand upon answers. 
o Give participant time to become comfortable and speak freely 
 
 Ask participant to read a GCOS-24 item. Question interpretability and meaning e.g.: 
o Could you re-phrase the question in your own words? 
o Was this question hard to understand, if so, why? 
o How would you make the question more clear/easy to understand? 
o What does [XXX] mean to you? 
 Prompt participant with open-ended questions e.g.: 
o Could you tell me more about [X]? 
 
 General GCOS-24 Questions e.g. 
o What are your overall thoughts of the questionnaire? 
o Are there any questions which you feel don’t fit in or seem different the others? 
o Is the layout / format of the questionnaire easy to understand? 
o Anything you would change to the questionnaire as a whole? 
o Did the questionnaire evoke any emotions? 
 
 Debrief 
o Thank them for taking part 
o Any further questions 
 
GCOS-24 questions will be addressed in a random order. Interviews should last around 45 minutes. A 
brief email of thanks will be sent to all participants. 
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Text copied from this letter of thanks will be used in email format. 
Date: XXXX 2017 
 
Dear XXXX,  
Many thanks for your recent participation in our research study. We are immensely grateful 
to have members of the public such as yourself who are willing to give up their time to 
support local research. Your contributions and comments were most helpful and will assist 
us in improving our questionnaire. 
 
Again I would like to pass on our thanks for taking part in our study, for your time and effort. 
 
If you have any questions, or if I can help in any way, please feel free to get in touch. 
Sincerely,  
Peter Grant 
Email: grantp2@cardiff.ac.uk  T: +44 (0)2920 744 055 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix E – Cognitive Interview Email of Thanks 
 112 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix F – Test-retest Recruitment Email 
 113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix F – Test-retest Recruitment Email 
 114 
 
 
 
 
 
Appendix F – Test-retest Recruitment Email 
 115 
 
 
Date: XXXX 2017 
 
Dear XXXX,  
Many thanks for your decision to take part in our research study. We are immensely grateful 
to have members of the public such as yourself who are willing to give up their time to 
support local research.  
You are halfway there! 
 
In two weeks you will be sent the same questionnaire again. This is the most important part 
of the study, because we are trying to judge whether people will give the same answers if 
they do it again. When the email comes through, we would greatly appreciate it if you took 
the time to fill out the questionnaire again.  
 
Again I would like to pass on our thanks for taking part in our study, for your time and effort. 
 
If you have any questions, or if I can help in any way, please feel free to get in touch. 
Sincerely,  
Peter Grant 
Email: grantp2@cardiff.ac.uk  T: +44 (0)2920 744 055 
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GCOS-24 Items: Item Characteristic Curves and Item Information Curves 
Item Characteristic Curves 
Cognitive Control: Items 1; 3; 12; 14; 18; 23 
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Decisional Control: Items 10; 13; 24 
 
 
 
 
 
Behavioural Control: Items 2; 5; 7; 9; 15; 16; 17; 22 
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Emotional Regulation: Items 4; 11; 21 
 
 
 
 
 
Hope: Items 6; 8; 19; 20 
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Item Information Curves 
Cognitive Control 
 
 
Behavioural Control 
 
 
 
 
 
Decisional Control 
 
 
Emotional Regulation 
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